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Abbreviations: 
11β-HSD1   11β-Hydroxysteroid Dehydrogenase type 1 
11β-HSD2   11β-Hydroxysteroid Dehydrogenase type 2 
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GR    Glucocorticoid Receptor   
GRE    Glucocorticoid Response Element 
H6PDH    Hexose-6-Phosphate Dehydrogenase 
LAS    Lanosterol Syntase 
LUS    Lupeol Synthase 
NADP+    Nicotinamide Adenine Dinucleotide Phosphate  
OSC    Oxidosqualene cyclase 
TEV    Tobacco Etch Virus 
TIPI    TEV protease Induced Protein Instability 
UGT    Uridine diphosphate dependent Glycosyltransferases 
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Glucocorticoids are hormones with a vital role in regulation of metabolic and defence responses. 
Their metabolism plays an important role in the pathogenesis of obesity, a major risk factor for 
metabolic syndrome, a collection of disorders such as insulin resistance, dyslipidemia and 
hypertension.  
At intracellular level the production of active glucocorticoids is regulated by two hydroxysteroid 
dehydrogenase enzyme isoforms 11β-HSD1 and 11β-HSD2, respectively. 11β-HSD2 is predominantly 
expressed in mineralocorticoid target tissues and acts as oxidase catalysing conversion of cortisol 
into cortisone. The isoform 11β-HSD1, expressed in a wide array of tissues and with highest levels in 
the liver, acts mainly as a reductase converting the cortisone into the biologically active hormone 
cortisol, in a NADPH dependent manner. Due to its implication in the metabolism of glucocorticoids, 
11β-HSD1 has become a primary target for the treatment of metabolic syndrome.  
In the last years many strategies have been developed for the screening of molecules with inhibitory 
effects against this target enzyme. All known approaches present unique features and are suitable 
for specific screening models. Nevertheless, due to the great therapeutic and economical interest 
around the treatment of metabolic syndrome, many research groups are constantly focused on the 
development of new and more successful strategies for identification of hits with improved 
pharmaceutical properties. 
In this study an innovative synthetic biology platform for synthesis and screening of 11β-HSD1 
inhibitors has been conceived and investigated. This strategy is based on the production of diverse 
chemical scaffolds in the yeast Saccharomyces cerevisiae, in which the molecules are directly 
screened through intracellular functional assays.  
Providing all necessary genetic information, the biosynthetic pathway of plant triterpenoids, a big 
class of natural compounds with many beneficial effects on human health, was reconstructed in the 
baker’s yeast. Moreover, by applying DNA family shuffling methods, a library of chimeric triterpenoid 
synthase cDNAs was constructed. The chimeric sequences, potential carriers of new enzymatic 
functions, were assembled together with the wild-type molecules in expressible yeast artificial 
chromosomes (eYACs). 
Furthermore, the construction of two yeast assays strains functionally co-expressing the murine 
glucocorticoid receptor (GR) and the human 11β-HSD1 enzyme is presented. In both developed 
strains, with different mechanisms, the reductase activity of the enzyme 11β-HSD1 on cortisone is 
connected with an easily detectable fluorescent signal. Cells that produce compounds with inhibitory 
activity against 11β-HSD1 can be identified through changes in fluorescence and isolated to further 
investigate the active molecules. The developed yeast-assays were validated using carbenoxolone, a 
Rosario Vanella  Abstract 
10 
 
known 11β-HSD1 inhibitor, and may represent useful tools for a first quick and easy screening of 
large number of membrane permeable putative inhibitory compounds. 
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Metabolic syndrome 
Metabolic syndrome or syndrome X is a constellation of associated conditions such as increased 
blood pressure, high blood sugar level, excess body fat around the waist and abnormal cholesterol 
levels that occur together, increasing the risk of heart diseases, stroke and diabetes. In the last years, 
due mainly to the sedentary life style, the increasing prevalence of these conditions together with 
progression of obesity and diabetes around the world, have made metabolic syndrome an important 
public health concern (Levesque and Lamarche, 2008).  
Metabolic abnormalities found in diabetes and metabolic syndrome are similar to those observed in 
the syndrome of prolonged glucocorticoid excess in blood (Cushing’s syndrome) (Day, 2007). In 
Cushing’s syndrome high production and high circulating levels of cortisol cause impaired glucose 
metabolism, decreasing glucose uptake in the peripheral tissues, enhancing the glucose production 
in the liver and decreasing the insulin production from pancreatic β-cells (Stahn et al., 2007).  
Despite the high similarity of clinical conditions between metabolic and Cushing syndromes, obese or 
metabolic syndrome patients have normal or lower glucocorticoids levels in blood compared with 
patients suffering of Cushing’s syndrome. This aspect led to the understanding that a tissue-specific 
peripheral activation process of these steroid hormones might be involved in pathogenesis of the 
conditions characterizing metabolic syndrome.  
 
 
Glucocorticoid hormones 
Glucocorticoids and mineralocorticoids are essential endocrine hormones involved in the regulation 
of many physiological processes. Mineralocorticoids, such as aldosterone in humans, principally 
stimulate epithelial sodium transport and regulate blood pressure (Agarwal and Mirshahi, 1999). 
Glucocorticoids (GCs) are named on their primary role in glucose metabolism. They promote 
gluconeogenesis in the liver and oppose the action of insulin by directly inhibiting β-cells insulin 
secretion in the pancreas. They also have important functions in amino acids metabolism, immune 
system and adaptive response to physical and psychological stress (Baxter, 1974; Rhen and Cidlowski, 
2005). 
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Both, glucocorticoid and mineralocorticoid hormones exert their functions upon binding to 
intracellular receptors, glucocorticoid and mineralocorticoid receptor respectively, with subsequent 
stimulation or repression of target genes transcription. 
The biological activity of glucocorticoids relies on the presence of a hydroxyl group at position C-11 of 
the steroid structure. Cortisol in human and corticosterone in rodents are active steroids whereas 
cortisone and 11-dehydrocorticosterone, possessing a C-11 cheto group, are inactive molecules. 
In humans, cortisol and part of cortisone are released under dynamic circadian and ultradian 
regulation by the hypothalamic-pituitary-adrenal axis and their rise in blood levels inhibits further 
release in a classic endocrine negative feedback loop (Biddie et al.2012). Cortisol is secreted in 
relatively high amount (15mg/day), but more than 90% of circulating hormone is bound to alpha 2-
globulin, a cortisol binding globulin (Cope and Black, 1958; Esteban et al., 1991). Only free cortisol is 
biologically active and can be converted into cortisone in peripheral tissues (Andersen, 2002).  
While cortisol is mainly secreted from the adrenal gland, the level of circulating cortisone in human 
body depends mainly on the peripheral conversion of cortisol (Tortorella et al., 1999). The low 
affinity between cortisone and alpha 2-globulin ensures similar circulating levels of free cortisone 
and free cortisol, despite the lower level of secreted cortisone (Meulenberg and Hofman, 1990).  
The local metabolism of glucocorticoids is regulated by the enzymes 11β-HSD1 and 11β-HSD2 that 
modulate the intracellular availability of cortisol for the binding to glucocorticoid receptor (GR). The 
receptor in its unloaded form resides in the cytoplasm bound to chaperone proteins (Funder, 1996), 
then upon ligand binding, GR undergoes a conformational change and after dimerization translocates 
into the nucleus where it can exert its trans-activation and trans-repression actions. 
Diversity in GR signaling is determined by the action of different glucocorticoid-response elements 
(GREs) and multiple receptor isoforms generated by alternative splicing and alternative translation 
initiation (Oakley and Cidlowski, 2011). Additionally, multiple post-translational modifications 
including phosphorylation, acetylation, ubiquitination, and SUMOylation can alter the function of this 
transcription factor (Anbalagan et al., 2012). 
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11β-HSD enzymes 
As described for the first time several decades ago, at a tissue-specific level the interconversion of 
glucocorticoids depends on the 11β-HSD enzymes (Berliner and Dougherty, 1961; Atanasov and 
Odermatt, 2007). 11β-HSD1 and 11β-HSD2 act as chemical switches converting the active hormone 
cortisol into the inert cortisone and vice versa, regulating the intracellular availability of cortisol to 
the glucocorticoid receptor.  
11β-HSD1 and 11β-HSD2 are products of separate genes and have different tissue distributions and 
physiological roles. The tridimensional structures of these two enzymes are similar with structurally 
conserved nucleotide cofactor binding and active sites. Nevertheless they share just the 18% of 
overall identity between their amino acid sequences (Tsigelny and Baker, 1995; Chapman et al., 
2003). 
11β-HSDs belong to the short-chain dehydrogenases/reductases family of enzymes also known as 
short-chain alcohol dehydrogenases or secondary alcohol dehydrogenases (Nordling et al., 2002; 
Baker, 1996). The two isoforms seem to act in an antagonist manner: type 1 acts mainly as an 11-oxo 
reductase producing cortisol, while type 2 acts exclusively as a 11-hydroxyl dehydrogenase 
inactivating cortisol into cortisone (Fig. 2.1). 
 
 
Figure 2.1. Reactions catalysed by 11β-HSD enzymes. 
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11β-HSD2 is expressed predominantly in mineralocorticoid target tissues, such as salivary glands, 
colon and kidneys. Its role is to protect the nonselective mineralocorticoid receptor from the 
unspecific binding of cortisol. Impaired activity of 11β-HSD2 causes the “apparent mineralocorticoid 
excess syndrome” due to the over activation of the mineralocorticoid receptor upon cortisol binding 
(Mune et al., 1995). 11β-HSD2 is also highly expressed in the placenta and developing fetus, 
providing a potent barrier to maternal glucocorticoids (Seckl and Meaney, 2004). This isoform is a 
NAD+ dependent dehydrogenase and has a Km in the nanomolar range for glucocorticoids (Albiston et 
al., 1994; Escher et al., 1998). Localization studies demonstrate that the bulk of the 11β-HSD2 faces 
the cytosol and the N-terminal tail anchors the enzyme to the membrane of the endoplasmic 
reticulum (Naray and Fejes, 1996).  
The isoform 11β-HSD1 is found as homodimer (Zhang et al., 2005; Hosfield et al., 2005) and is 
expressed in a wide array of tissues, with highest levels in the liver, from where it was originally 
purified (Lakshmi and Monder, 1988). The encoding human gene, HSD11B1, is over 30 kb in length 
and consists of 6 exons localized on chromosome 1 (1q32.2–41). A cDNA of approximately 1.4 kb in 
length predicts an open reading frame of 876 bp and a protein of 292 amino acids (Fig. 2.2a). 
Expression in human is absent until 2–3 months of age, then rises until 1 year of age, when it reaches 
constant levels.  
11β-HSD1 structure can be divided into four important regions. The transmembrane domain enabling 
the enzyme to attach the membrane of ER with a short five amino acid region in the cytosolic side 
(Odermatt et al., 1999), the cofactor binding domain (Rossmann fold), the catalytic site, and the C-
terminal domain involved in the oligomerisation of the enzyme (Fig. 2.2b). 
Ser170, Tyr183, Lys187 and Asn111 are conserved residues of the catalytic site responsible for the 
substrate orientation, proton transfer and reaction intermediates stabilization (Filling, 2002; Hosfield 
et al., 2005). The enzyme has a Km in the range of μM for its glucocorticoid substrates and shows 
preference in binding cortisone rather than cortisol supporting the fact that in vivo it acts primarily 
on the cortisone as a reductase (Tannin et al., 1991; Stewart et al., 1994). 
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a. 
 
b. 
 
Figure 2.2. a) Amino acid sequence of 11β-HSD1 human enzyme. In bold are indicated the amino acids involved 
in the secondary conformation of the enzyme. Grey indicates helix and green indicates beta strands. 
 b) Tridimensional structure of human 11β-HSD1 homodimer. Red arrows indicate the amino-terminal end of 
each monomer. Green arrow indicates the C-terminus of the two monomers interacting in the homodimer 
complex (Protein Data Bank archive). 
 
 
Enzymatic studies of the liver 11β-HSD1 underlined a bidirectional conversion of GCs. This enzyme is 
able in fact to reduce cortisone into active cortisol with NADPH cofactor as source of protons, or to 
act as dehydrogenase on cortisol converting it to cortisone. Upon cell disruption the reductase 
activity of 11β-HSD1 is lost (Lakshmi and Monder, 1988; Duperrex et al., 1993; Low et al., 1994) and 
can be regained providing high levels of NADPH cofactor in the reaction environment (Walker et al., 
2001).  
From recent observations it is clear that the enzymological characteristics of 11β-HSD1 critically 
depend on its intracellular compartmentalization. The N-terminal tail of the enzyme anchors it to the 
endoplasmic reticulum (ER) membrane with the catalytic domain facing the lumen of the ER. Within 
the N-terminal tail two positively charged lysine residues on the cytoplasmic side and two negatively 
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charged glutamate residues in the luminal side are crucial for the correct orientation of the enzyme 
in the ER membrane (Frick et al., 2004). Exchange of N-terminal regions between the 11β-HSD1 and 
11β-HSD2 led to inverted orientation within the ER and both chimeric proteins resulted inactive 
(Odermatt et al., 1999).  
In the lumen of ER the enzyme 11β-HSD1 co-localizes and functionally depends from the hexose-6-
phosphate dehydrogenase (H6PDH), the microsomal isoform of the well-known glucose-6-phospathe 
dehydrogenase. H6PDH converts glucose-6-phosphate to 6 phosphogluconolactone generating the 
reduced cofactor NADPH (Atanasov et al., 2004; Bujalska et al., 2005) (Fig. 2.3). 
This enzymatic collaboration was finally confirmed through knock out mice lacking the H6PDH gene 
in which no conversion of the inactive glucocorticoid into corticosterone was detected (Lavery et al., 
2006). A protein-protein interaction between the two enzymes allows a fine tuning regulation of the 
11β-HSD1 activity due to the direct supply of NADPH from H6PDH (Atanasov et al., 2008).  
 
 
Figure 2.3. Schematic representation of glucocorticoids action mediated by 11β-HSD enzymes in human cells 
(Reproduced with permission from Odermatt et al., 2006).   
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11β-HSD1 and metabolic diseases 
Implication of 11β-HSD1 in the pathogenesis of metabolic diseases has been brought to light from 
investigations conducted on obese individuals that revealed a positive correlation between 
expression of this enzyme in subcutaneous adipose tissue and the percentage of body fat, waist 
circumference, fasting glucose and insulin resistance (Rask et al., 2002; Desbriere et al., 2006). 
Moreover, the importance of 11β-HSD1 and high levels of cortisol in adipose tissues has been 
elegantly demonstrated in transgenic mice experiments (Paterson et al., 2005). Mice with 11β-HSD1 
overexpression simulate a condition very similar to the metabolic syndrome, with elevated local 
levels of cortisol that antagonize the effects of insulin contributing to the development of insulin 
resistance and type 2 diabetes mellitus (Masuzaki et al., 2001; Fotsch and Wang, 2008). On the 
contrary, 11β-HSD1 knock out mice, are viable healthy models with adrenal hyperplasia and 
decreased production of active cortisol in the peripheral tissues. They showed a resistance to diet 
induced obesity and an improved lipid profile and glucose tolerance (Kotelevtsev et al., 1997; Morton 
et al., 2001). Similar results were obtained under disruption of 11β-HSD1 in an obesity/diabetes 
prone mice strain (Morton et al., 2004). 
Studies on animal models revealed the important role of 11β-HSD1 in the peripheral metabolism of 
glucocorticoids and made of this enzyme the most relevant target for the treatment of metabolic 
syndrome and its associated disorders. In fact, the inhibition of the 11β-HSD1 enzyme is a successful 
strategy for decreasing tissues cortisol accumulation and to treat the metabolic consequences of 
glucocorticoid receptor hyper-activation in peripheral tissues. 
 
 
Inhibition of 11β-HSD1  
Many natural and synthetic compounds have been investigated for their ability to inhibit the enzyme 
11β-HSD1. One of the first described natural inhibitor is glycyrrhetinic acid, a triterpenoid found in 
liquorice root (Glycyrrhiza glabra) and already used in traditional medicine for thousands of years 
thanks to its beneficial effect on human health (Monder et al., 1989) (Fig. 2.4a). 
In the selection process of new putative inhibitors against the 11β-HSD1 enzyme, different properties 
of the tested compounds, such as species-specific effects and specificity, have to be evaluated. 
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Since numerous in vivo pharmacological studies are carried out in rodents, it is necessary for 
inhibitors of human 11β-HSD1 to also inhibit the rodent enzyme. The crystal structures of rodent and 
human 11β-HSD1 are considerably different with a similarity of 77% at the amino acid level (Tannin 
et al., 1991). Therefore, a compound able to inhibit the human enzyme will probably not have the 
same effect and strength on the rodent enzyme. This is, for example, the case of 
arylsulfonamidothiazole compounds that show different behaviours towards 11β-HSD1 enzymes 
found in different species. In contrast the carbenoxolone, hemisuccinyl ester of glycyrrhetinic acid, is 
able to strongly bind and inhibit both the mouse and human enzymes with similar effects (Su et al., 
2008) (Fig. 2.4b).  
 
a. 
 
b. 
 
Figure 2.4. a) Chemical structures of two common 11β-HSD1 inhibitors. b) Tridimensional structure of human 
11β-HSD1 homodimer complex. The two monomers (red and blue) interact with carbenoxolone (yellows halos) 
in the catalytic pocket (Protein Data Bank archive).  
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In the screening processes for new 11-βHSD1 inhibitors complementary studies concentrate on the 
specificity of the candidate molecules, studying their effects towards others human enzymes 
(Arampatzis et al., 2005). In the case of 11β-HSD1 inhibition, the typical direct association for a 
specificity control of a candidate molecule is to study its effects against the 11β-HSD2 enzyme. In 
fact, as for glycyrrhetinic acid and carbenoxolone, intensive therapeutic programs employing 11β-
HSD1 inhibitor with strong inhibitory effect also on the isoform 2 would cause important 
consequences as sodium retention, hypokalemia and hypertension (Kotelevtsev et al., 1999; Sandeep 
et al., 2004). However, the lack of specificity might affect also other enzymes with high similarity to 
11β-HSD1 such as retinol dehydrogenases and 17β-HSD that, structurally related with 11β-HSD1, if 
improperly inhibited would cause important health issues (Robinzon et al., 2003).  
All known 11β-HSD1 inhibitors can be divided in several groups: endogenous substances, exogenous 
natural products and their derivatives and synthetic small organic molecules. 
Several endogenous steroids, including progesterone and its metabolites, androgen metabolites and 
many bile acids have been reported to act as 11β-HSD1 inhibitors although their effect is not specific 
and rather weak (Morris et al., 2004). Among the natural occurring 11β-HSD1 inhibitors, 
glycyrrhetinic acid and its derivative carbenoxolone are the most used compounds for inhibition of 
11β-HSD1 in “proof of concept” experiments. Nevertheless, as already mentioned before, they lack 
of specificity with respect to the 11β-HSD2 and, moreover, carbenoxolone seems to have limited 
ability to penetrate adipose tissue where the effect of the 11β-HSD1 inhibition should be crucial to 
lighten insulin resistance (Sandeep et al., 2005). Flavonoids from fruits and vegetables are other non-
selective 11β-HSD1 inhibitors (Lee et al., 1996) and also coffee has been tested and some of its 
components showed a strong inhibitory effect and high specificity towards 11β-HSD1 (Atanasov et 
al., 2006). In addition, many synthetic molecules like adamantly triazole and 2 aminothiazole 
sulfonamide have shown good inhibition and specificity against 11β-HSD1 (Barf et al., 2002; 
Hermanowski-Vosatka et al., 2005).  
Most of the approaches used for selection of candidate inhibitors employ liver microsomes or 
recombinant mammalian cell lines expressing 11β-HSD1 as source of the enzyme and analyse cortisol 
and cortisone contents through Liquid Chromatography-Mass Spectrometry (Xu et al., 2006). Other 
strategies involve the stable heterologous expression of 11β-HSD1 combined with β-galactosidase 
reporter constructs under control of glucocorticoid response elements (Barton et al., 2004).  
Moreover, in-silico approaches, such as pharmacophore modelling, are extensively used. These 
methods generally study the electrostatic and steric features that are necessary for an optimal 
interaction of a small molecule with its biological target (enzyme, receptor) and allow for selection of 
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hits through the screening of huge virtual library of compounds (Schuster et al., 2006; Vuorinen et al., 
2014). 
All these strategies represent powerful tools to filter and select active compounds from large 
libraries of molecules. Nevertheless they often require the use of hazardous radioactive substances 
or the use of colorimetric materials that can interfere with the tested molecules and they can require 
expensive instrumentation and expertise. Therefore, due to the large economic and pharmaceutical 
interest around the inhibition of this target enzyme, many research groups are still focused on 
development of more efficient strategies that using innovative screening systems, enable to isolate 
molecules with improved therapeutic effects. 
 
 
Triterpenoids 
Among all the molecules investigated for the inhibition of 11β-HSD1, natural compounds have 
attracted much attention. Historically, in ancient eastern medicine practices, many plant extracts 
were used for their important and relevant effects on human health. In fact, studies of roots and 
bulks extracts with antidiabetic properties has allowed for the identification of interesting natural 
compounds that affect the function of 11β-HSD1 in the metabolism of glucocorticoids (Gumy at al., 
2009). Many classes of natural compounds like flavonoids (Schweizer et al., 2003), plant polyketides 
and triterpenoids (Blum et al., 2009) have been described to have inhibitory effects on 11β-HSD 
enzymes. Particularly triterpenoids have attracted high attention during the last years due to their 
wide applications in medicine with anti-inflammatory (Tapondjou et al., 2008; Sun et al., 2010), anti-
cancerogenic (Man et al., 2010) anti-bacterial (Saleem et al., 2010) anti-fungal and antiviral effects 
(Coleman et al., 2010; Rattanathongkom et al., 2009). 
Triterpenoids represent a large group of plant natural compounds with more than 20’000 known 
members. They are synthetized from the condensation of five-carbon building blocks of the 
mevalonate pathway in fifteen-carbon building block units of farnesyl pyrophosphate (FPP). Two FPP 
are then fused to form 2-3 oxidosqualene (Kirby and Keasling, 2009). The cyclization of the 30-carbon 
intermediate oxidosqualene, catalysed by oxidosqualene cyclases (OSCs) also known as triterpenoids 
synthases or cyclases, represents the first distinct step in the synthesis of triterpenoids (Fig. 2.5). This 
class of molecules includes sterols, as lanosterol and cycloartenol, steroids, and triterpenoid 
saponins. In general, animals and fungi have only one oxidosqualene cyclase, called lanosterol 
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synthase (LAS), needed for production of membrane sterols and steroids. In plants, cycloartenol 
synthase (CAS) is widely distributed but also LAS is represented in some species (Suzuki et al., 2006). 
These two enzymes convert oxidosqualene through the protosteyl cation intermediate in different 
triterpenoid backbones. Many other cyclases have evolved from common ancestral CAS (Lodeiro et 
al., 2005) and are able to synthetize different triterpenoid frameworks (Ohyama et al., 2009; Xu et 
al., 2004).  
Among the OSCs two of the more represented in plants are the lupeol synthases (LUS) and β-amyrin 
synthases (bAS). LUSs and bASs cyclize oxidosqualene through dammarenyl cation in order to form 
lupeol and β-amyrin, respectively. Lupeol, β-amyrin and their diverse metabolites are implicated in 
various plant processes and seem to act in plants as protective agents against parasites and insects 
(Augustin et al., 2011). 
 
 
Figure 2.5. Schematic representation of the triterpenoids biosynthetic pathway. The most common 
triterpenoid backbones are represented. bAS= beta-amyrin synthase; LUS= lupeol synthase; CAS= cycloartenol 
synthase; UTG= uridine diphosphate glycosyltransferases (Reproduced with permission and adapted from  
Hayashi et al. 2003).  
 
 
Rosario Vanella  Introduction 
23 
 
The diversity of plants triterpenes emanates not only from the radiation of the triterpenoid synthase 
genes family but also from the ability of some family members to contribute multiple products 
(Morita et al., 2000; Segura et al., 2000). The oxidosqualene cyclases that produce multiple products, 
classified as “multifunctional”, are not yet deeply understood from the enzymatic point of view. 
However, some researches have confirmed, through mutagenesis and directed evolution 
experiments, that evolution progresses are responsible for big changes in product diversity formation 
from a single parental enzyme (Segura et al., 2003).  
In plants, after the cyclization of the 2-3 oxidosqualene into the basic triterpenoid backbones, the 
resulting molecules are always modified trough reactions performed by P450 monooxygenases and 
uridine diphosphate dependent glycosyltransferases (UGTs) (Hamberger and Bak, 2013). 
P450s act on specific substrates and allow the modification in a target position of the backbone. Due 
to the high number of P450s present in plants (1% of all protein encoded) many modifications as 
hydroxyl, keto-, aldehyde- and carboxyl- groups can be found in the final molecules. This first step of 
modification contributes to increase the number of different triterpenoids present in nature (Seki et 
al., 2015). The primary modification can also be followed by other decoration steps as the linkage of 
complex side groups or formation of intramolecular bridges between adjacent functional groups. 
Glycosylation presumably involves sequential activity of different enzymes belonging to the 
multigene family of UGTs that catalyse the transfer of activated glycosyl residues from uridine sugar 
nucleotides to a vast array of acceptor molecules (Vogt and Jones, 2000; Ross et al., 2001). Once 
glycosylated, triterpenoid saponins increase their water solubility and acquire specific activity in the 
plant organism.  
Among their many industrial applications, during the last decades high interest has been focused on 
selection or development of triterpenoid molecules with inhibitory effect on enzyme 11β-HSD1. 
Glycyrrhetinic acid and its derivative carbenoxolone have been found to have potent effects in the 
11β-HSD1 inhibition. Glycyrrhetinic acid is a triterpenoid found mainly in roots of Glycyrrhiza glabra 
and derives from the triterpenoid backbone of β-amyrin. All the enzymes responsible for the 
synthesis of this triterpenoid have been studied through coupling of phytochemical approaches and 
analytical chemistry.  β-amyrin synthase of G.glabra was identified in 2001 (Hayashi et al., 2001) and 
the P450s (CYP88D6 and CYP12A154) responsible for the modifications at position C-11 and C-30 of 
β-amyrin have been identified from their natural source and their activities were confirmed in yeast 
(Seki et al., 2008 and 2011) (Fig. 2.6). Currently, glycyrrhetinic acid is used as important lead 
compound for designing of analogues with more specific inhibitory effects on the human enzyme 
11β-HSD1 (Su et al., 2007; Beseda et al., 2010). 
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Figure 2.6. Proposed pathway for the synthesis of glycyrrhetinic acid. The P450 enzymes CYP88D6 and 
CYP72A154 are responsible for the secondary modifications on the β-amyrin backbone (Reproduced with 
permission from Seki et al., 2011). 
 
 
An additional reason of the large number of triterpenoids present in nature can be addressed to the 
evolutionarily plasticity of the triterpenoid synthases that readily change and acquire new catalytic 
properties (Trapp and Croteau, 2001). This feature has allowed this family of enzymes to expand and 
form high number of members displaying different catalytic features. Change in residues that 
sterically distort the catalytic domain of the enzyme could lead easily to a change in the final product 
of the cyclization processes. Application of random mutagenesis approaches such as DNA shuffling or 
random points mutagenesis have allowed changes in product specificity of triterpenoid synthases 
leading to the formation of different products with respect to the original ones (Wu and Griffin, 
2002; Segura et al., 2003).  
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In the last decades the great medical and economical interest around the treatment of metabolic 
syndrome and related disorders has been the propellant force leading to the identification of 
pharmaceutical compounds with inhibitory activity against the human enzyme 11β-HSD1. In fact, 
with its pivotal role in glucocorticoids metabolism, 11β-HSD1 represents the main pharmaceutical 
target for treatment of metabolic syndrome. 
Screenings of chemical libraries and natural molecules represent the main sources of new inhibitors 
and are supported by valuable assay systems where the function of the target enzyme can be easily 
investigated. However, these traditional screening approaches usually explore just small fractions of 
the natural chemical diversity.  
This work aims at the construction of a synthetic biology platform for the synthesis, screening and 
identification of 11β-HSD1 inhibitors. This strategy is based on the production of diverse chemical 
scaffolds in the yeast Saccharomyces cerevisiae, in which the molecules are directly screened through 
intracellular functional assays. The synthesis of novel compounds is based on reconstitution of 
biosynthetic pathways, known to be source of drug-relevant chemical scaffolds, in the host organism 
through providing the appropriate genetic information. In addition, the chemical variability 
synthetized can be further increased by providing genetic sequences with unknown functions that 
can reveal new enzymatic activities (Klein at al., 2014) (Fig.3.1).  
 
 
 
Figure 3.1. Schematic representation of the strategy investigated within this PhD thesis. 
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The application of the synthetic biology platform for synthesis and screening of human 11β-HSD1 
inhibitors can be divided into three sections: 
 
1) Selection of genetic information for reproduction of natural drug-relevant pathways in yeast: 
In this work, the biosynthetic pathway of triterpenoids was selected as source of drug-relevant 
genetic information. Triterpenoids are mainly represented in plants and belong to terpenoids, the 
biggest class of natural compounds. Several beneficial effects on human health have been attributed 
to these molecules and many representatives are currently used for prevention and treatment of 
different pathological conditions. Various components of this class have been demonstrated to have 
inhibitory effects on the 11β-HSD1 enzyme, but generally, due to low target specificity, they cannot 
be used intensively in therapy. For these reasons further investigations within this class of 
metabolites represent a successful strategy for identification of more specific inhibitors of the target 
enzyme. 
Natural synthesis of triterpenoids is an elaborated biochemical process that involves cyclization of 
squalene molecules into complex 30 carbons scaffolds that can be further modified by addition of 
functional chemical groups. The whole pathway is difficult to be reproduced through synthetic 
chemistry and in some cases not all steps involved are clearly defined. Therefore for many years the 
main source of these compounds was the extraction from their natural plant producers. However 
this step represented a bottle neck for the study of their pharmaceutical properties due to low yields 
and purity of the extracts. In order to overtake these limitations, strategies based on metabolic 
engineering of microorganisms represent valuable alternatives.  
Here, the biosynthetic pathway leading to production of plant triterpenoids is reconstituted in yeast 
Saccharomyces cerevisiae by using eYACs (expressible Yeast Artificial Chromosomes). eYACs allow for 
the expression of large numbers of heterologous genes in yeast providing all the essential genetic 
information for the assembly of the biosynthetic pathway of triterpenoids. 
Yeast cells are ideal host organisms for the synthesis of this class of natural compounds, given the 
fact that squalene and 2,3-epoxy-squalene, the common precursors to all triterpenoids, are 
produced in yeast as precursors of ergosterol. Therefore, the endogenous ergosterol pathway can be 
exploited for production of these plant metabolites, providing the yeast with the exogenous genetic 
information that leads from epoxy-squalene to synthesis of the triterpenoid backbones and their 
functionalized derivatives (Fig. 3.2). 
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2) Construction of new genetic information in order to increase the variability of compounds 
synthetized in yeast: 
Trying to extend the variability of the chemical structures synthetized in the yeast cells, unknown 
genetic information are also sourced to the host organism. These information lead to the expression 
of new enzymes with distinct catalytic activities that can originate new chemical scaffolds or modify 
the pre-synthetized ones. 
To this purpose, in this thesis, a group of cDNA molecules codifying for natural triterpenoid cyclases 
(β-amyrin-, lupeol-, and cycloartenol- synthases) is subjected to protein engineering methods. The 
resultant chimeric sequences are collected in a large chimeric cDNA library generated by DNA 
shuffling procedures, and included in the eYACs preparation. Reiterative cycles of shuffling has 
proved to be a useful approach for the evolution of single gene products with enhanced activity, 
altered substrate and product specificity (Crameri et al., 1998). 
Finally, the genetic information provided by eYACs, including natural triterpenoid synthase cDNAs 
and mutant triterpenoid cyclase sequences, can be further increased with a collection of genes 
codifying for “decoration” enzymes (e.g. P450 oxygenases, glycosyltransferases etc.) that enable to 
modify the chemical scaffolds produced, dramatically enhancing their variability.  
Altogether these elements aim to increase the diversity of compounds that can be synthetized in 
yeast and give access to a broad chemical diversity for screening of pharmaceutical active 
compounds against the enzyme 11β-HSD1 (Fig. 3.2). 
 
 
Figure 3.2. Reconstitution of the triterpenoid biosynthetic pathway in yeast using the eYAC approach. Natural 
and chimeric triterpenoid synthases are responsible for the conversion of squalene or 2,3 epoxy-squalene in 
different chemical scaffolds. Decorating enzymes can act on the pre-synthetized frameworks and modify them 
through addition of functional groups. 
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3) Construction of yeast based screening assays for identification of human 11β-HSD1 inhibitors: 
The synthetic biology platform investigated in this thesis is based on the potential of yeast as model 
organism. Yeast cells represent not only the producers of diverse chemical scaffolds, but in addition 
the screening systems for the effects of the new synthetized compounds versus the pharmaceutical 
target, the human enzyme 11β-HSD1. 
In order to screen the large collection of compounds that can be produced in yeast by the eYAC 
approach and to avoid long and complex purification processes, the molecules are meant to be 
directly tested at intracellular level through efficient yeast based assays in which the activity of 11-
βHSD1 is connected with a fluorescent output. Molecules that exert inhibitory activity cause 
intracellular changes of fluorescence and the yeast cells producing inhibitor compounds can be 
identified and sorted by FACS.  
 
 
This thesis in particular describes: 
 
- The construction of a large library of chimeric triterpenoid synthase cDNAs through 
application of DNA family shuffling procedures.  
 
- The assembling and transformation of eYAC molecules for simultaneous expression of 
triterpenoid cyclases (natural and chimeric) and the investigation of their capacity for 
synthesis of triterpenoid molecules in yeast.  
 
- The construction, testing and validation of two yeast assay strains where the activity of 
human enzyme 11β-HSD1 is connected to a fluorescent output through different 
mechanisms. 
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Evolutionary methods  
In the present chapter the study and the application of DNA evolutionary strategies to three groups of natural 
triterpenoid synthase cDNAs is described. The new DNA chimeric molecules, together with cDNAs of natural 
triterpenoid synthases and “decorating” enzymes, were aimed to be assembled in eYACs for multiple and 
simultaneous expression in the yeast Saccharomyces cerevisiae. Yeast cells provided with these genetic 
information contain all the essential elements for synthesis of plant triterpenoids and presumably other 
unknown chemical scaffolds to be screened for 11β-HSD1 inhibition.  
 
 
Despite continued advances in the understanding of enzymes structures and functions, it is clear that 
many aspects of enzyme activity cannot be predicted. It is for this reason that strategies for protein 
engineering attract large consensus. 
Evolutionary methods in biology are potent strategies for the in vitro evolution of enzymes and tend 
to mimic the natural process of evolution speeding it up by direct in vitro selection. The most 
successful and applied techniques rely on heterologous recombination of fragments from related 
natural genes for construction of large libraries of new chimeric molecules. These strategies, based 
on fragments recombination, allow to investigate the functions of amino acid domains or to 
randomly introduce modifications in the new mutant enzymes. 
Generally, for the application of these protocols not deep information on the enzymes activity are 
needed and the large amount of chimeric sequences produced represents a promising source for 
isolation of new interesting enzyme variants. In fact, it has been extensively demonstrated that 
properties such as productivity, substrate and product specificities or reaction mechanism of an 
enzyme can be changed dramatically through application of these methods (Stemmer, 1994; Crameri 
et al., 1998; Zhang et al., 1999; Ness et al., 1999).  
In order to create a large cDNA chimeric library searching for new enzymatic activities, ten cDNA 
molecules, codifying for natural triterpenoid synthases, have been selected for the application of two 
DNA shuffling methods. The selected molecules codify for three of the most common classes of 
triterpenoid cyclases present in plants: cycloartenol-, β-amyrin- and lupeol- synthases (Table 4.1). 
The expression and functionality of these classes of enzymes have been previously described in yeast 
(Corey et al., 1993; Herrera et al., 1998; Iturbe-Ormaetxe et al., 2003).  
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 Table 4.1. Triterpenoid cyclase cDNAs used in the application of DNA shuffling protocols.  
cDNA  Name Abbreviation Source Accession number 
EV42 Lupeol Synthase LUS Arabidopsis thaliana NM_179572 
EV43 Lupeol Synthase LUS Ricinus communis DQ268869 
EV47 β-amyrin synthase bAS Medicago truncatula AF478453 
EV48 β -amyrin synthase bAS Glycyrrhiza glabra AB037203 
EV49 β -amyrin synthase bAS Panax ginseng AB009030 
EV50 β -amyrin synthase bAS Panax ginseng AB014057 
EV52 Cycloartenol synthase CAS Lotus japanicus AB181246 
EV53 Cycloartenol synthase CAS Glycyrrhiza glabra AB025968 
EV54 Cycloartenol synthase CAS Panax ginseng AB009029 
C405 Cycloartenol synthase CAS Pisum sativum D89619 
 
 
Triterpenoid synthase enzymes have a high evolutionary plasticity and readily change acquiring new 
catalytic properties (Trapp and Croteau, 2001). Studies on their evolution have suggested that they 
all derived from a common ancestral molecule through an intense evolutionary process (Xue et al., 
2012). Cycloartenol synthases (CAS) are considered the common ancestral oxidosqualene cyclases 
and have proven to be excellent targets for mutagenesis, easily acquiring new catalytic properties 
(Wu and Griffin, 2002; Meyer et al., 2002). They were the first plant triterpene synthases identified 
through complementation experiment in a lanosterol synthase mutant yeast (Corey et al., 1994). 
β-amyrin and lupeol synthases represent a distinct catalytic class with respect to cycloartenol 
synthases and produce non-steroidal triterpenoids. These cyclases arose recently and are only 
represented in dicotyledonous plants (Segura et al., 2003). Their amino acid sequences generally 
share high similarity despite generating different products. Random mutagenesis studies 
demonstrated high plasticity of these enzymes that efficiently interchanged their product specificity 
(Shibuya et al., 1999).  
Moreover, β-amyrin cyclases (bAS) catalyse the synthesis of β-amyrin, precursor of glycherretinic 
acid, one of the most studied inhibitors of 11β-HSD1 (Seki et al., 2011). Random mutagenesis of this 
enzyme might represent a promising strategy to generate changes in its reaction mechanism in order 
to produce new interesting chemical scaffolds with stronger and more specific inhibitory effect 
against 11β-HSD1.  
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Different works, through mutagenesis approaches, have demonstrated the flexibility of these 
enzymes in switching their catalytic properties, for example conversion of a cycloartenol synthase 
into a lanosterol synthase (Wu and Griffin, 2002). However, no mutations of triterpenoid synthases 
that lead to synthesis of novel and new-to-nature triterpenoid scaffolds have been described. In this 
work, in order to create mutants of triterpenoid synthases able to produce diverse chemical 
scaffolds, a random approach was preferred to direct mutagenesis methods. In fact, little 
information is available on enzyme domains or single amino acids responsible for radical changes in 
the catalytic mechanism of the triterpenoid synthases. Thus, the construction of chimeric gene 
libraries, through swapping domain methods, could provide a large source of new chimeric 
molecules that allows for selection of interesting and not predictable enzyme variants. 
All cDNA molecules used in this work were synthetized with an optimized codon usage for efficient 
expression in yeast Saccharomyces cerevisiae. 
The application of DNA shuffling methods requires a certain homology between the DNA molecules 
involved in order to allow for an efficient recombination of the fragments during the reassembling 
process. For this reason the molecules have been organized into three groups of four cDNA 
sequences according to their similarity values. β-amyrin synthases and Cycloartenol synthases were 
organized in two different groups according to their original enzyme family. A third mixed group was 
assembled with cDNAs of two β-amyrin and two lupeol syntases, different enzymes that catalytically 
act on the 2,3 epoxy-squalene with similar mechanisms. The DNA sequences in each pre-assembled 
group of molecules shared high nucleotide similarity, from   ̴73% to   8̴6%. (Fig. 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Rosario Vanella  Results and Discussions 
34 
 
a. Beta-amyrin synthase and Lupeol synthase cDNAs   
 
                                                             b. Beta-amyrin synthase cDNAs 
 
c. Cycloartenol synthase cDNAs 
 
 
Figure 4.1. Nucleotide similarity values between the sequences of triterpenoid cyclase cDNAs organized in 
three different groups for the application of DNA shuffling methods. 
 
 
In order to evaluate the best experimental conditions for the construction of chimeric DNA libraries 
different protein engineering methods were investigated. 
On the basis of the original DNA family shuffling protocol (Crameri et al., 1998) an equimolar mixture 
of cDNAs, PCR amplified, was subjected to DNaseI restriction reaction. The mixture of randomly 
generated fragments was further purified and reassembled in a primerless PCR step, in which no 
other DNA content was added. During the reassembling PCR, through reiterative steps of 
denaturation, annealing and elongation, the fragments primed to each other based on their 
homology and recombined to form full length molecules (Fig. 4.2). 
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Figure 4.2. Graphic representation of the steps involved in a typical DNA family shuffling process. The parental 
molecules, indicated by different colours, are organized in equimolar mixture and randomly digested by 
DNaseI. DNA fragments are collected and used in a reassembly (primerless) PCR. Final chimeric molecules are 
PCR amplified from the mixture by adding universal external primer. 
 
 
The successful application of the DNA family shuffling method required a precise control of the 
DNaseI digestion reaction to obtain fragments of desired length and an efficient reassembling 
process during the primerless PCR. The favourable outcome of these evolutionary strategies depends 
on the efficient recombination of heterologous fragments during the primerless PCR based on 
reiterative denaturation and annealing steps.  
In this case the protocol was successfully adapted in order to obtain amplification of full length final 
molecules that indicated correct conditions for the reconstruction of the sequences. Nevertheless, 
this aspect did not confirm that conditions were optimal for heterologous recombination during the 
primerless PCR. In fact, sequences analysis revealed low recombination rates (1 to 6 recombination 
events) per molecule and high presence (at least  2̴5%) of parental non-modified molecules in the 
mixture. Parental molecules were found at higher percentages especially in the mixed group of 
lupeol and β-amyrin synthase cDNAs (Fig. 4.1a) where a lower presence of high homology regions, 
favourable for recombination between the molecules, promoted the reassembly of wild-type 
sequences during the primerless PCR.  
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Strong presence of point mutations with a rate of  ̴0.5% were detected in the final mix of molecules 
and often caused the appearance of stop codons and, therefore, translation of truncated non-
functional enzymes. In fact, the enzymatic DNA fragmentation used in this method most likely 
contributed to create very small DNA fragments that could prime to homologous regions causing 
single nucleotide mismatches during amplification. In addition a laborious control of the DNaseI 
reaction due to the relatively long nature of the starting cDNAs (2.3 Kb) did not guarantee easy 
handling and reproducibility of this method.  
All these reasons and the absence of a direct high-throughput screening system to easily isolate the 
recombinant functional DNA molecules in millions of new products led to the investigation of new 
strategies for the construction of chimeric DNA libraries with minimal contamination of unmodified 
parental sequences and high control of the recombination process. 
A new method inspired by the “degenerate oligonucleotide gene shuffling” (Gibbs et al., 2001) was 
finally conceived and properly adapted for the purposes of this work.  
This method is a semi-synthetic DNA family shuffling process with few but relevant differences with 
respect to the DNA family shuffling protocol previously employed. The use of DNaseI is avoided and 
substituted with PCR amplification of short overlapping fragments from the starting sequences. The 
regions selected for primers design correspond to the regions of reassembly of the DNA fragments 
during the primerless PCR (Fig. 4.3). Therefore, in this case, recombination is guided by the operator 
and strictly based on sequence homology. This semi-synthetic shuffling method does not allow for a 
random fragmentation but provides flexibility and full control of the number and position of possible 
crossover events in the chimeric final products. Moreover, it gives the ability to drive the shuffling of 
part of the genes and single DNA domains for more precise domain-function investigations (Fig. 4.3). 
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Figure 4.3. Schematic representation of the DNA semi-synthetic shuffling protocol. Different colours indicate 
different parental molecules processed together. Overlapping DNA fragments are amplified from all the 
starting sequences. Equimolar mixture of the fragments are set and subjected to recombination PCRs where 
the fragments can overlap and recombine until the full length molecules are created. Final amplification with 
external primers ensures the preparation of the new sequences for cloning and further analyses (Ritler D. 
bachelor thesis). 
 
 
First, for each group of triterpenoid synthase cDNAs to be processed, the DNA regions with highest 
similarity have been identified. Based on these regions, short overlapping common primers (10-15 
bp) of opposite orientation were designed and used for the PCR amplification of DNA fragments. The 
primers bound efficiently to the DNA of all members of the same group in each conserved region 
selected (Fig. 4.4a). Ten couples of common primers plus two universal primers designed upstream 
and downstream of the sequences (within the recipient vector) were used for the amplification of 
eleven DNA “bricks” (100 -500 bp) from each member of the group (Fig. 4.4b).  
Overlapping primers with opposite orientation, designed on the same conserved regions, 
represented the extreme overlapping ends of two adjacent amplified DNA fragments and were 
responsible for subsequent recombination processes in the primerless PCR (Fig. 4.4b). In fact, the use 
of a common pair of primers for the amplification of each fragment from all the different starting 
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molecules ensured that the overlapping regions between two adjacent fragments were identical, 
whether these were amplified from the same sequence (homo) or from different sequences (hetero) 
of the group. Therefore, as a consequence, formation of hetero-duplex and homo-duplex 
recombination events during primerless PCR had the same probability to occur. This feature was 
specifically conceived to enhance the number of recombination events in the final mix of molecules. 
 
a. 
 
b. 
 
Figure 4.4. a) Example of primers designed for the semi-synthetic DNA shuffling. The cDNA sequences are 
aligned and one conserved regions is shown (bold). Short primers able to bind efficiently all the four templates 
were generated. Red nucleotides indicate mismatches in the sequences alignment. b) Schematic 
representation of cDNAs in the original recipient plasmid. Arrows indicate the primers used for fragments 
amplification. Two fragments are represented to emphasize the ending common regions of the DNA “bricks” 
that allow recombination during the primerless PCR. Different colours indicate different cDNAs treated 
together. 
 
 
All DNA fragments generated from the same group of cDNA molecules were organized in equimolar 
mixtures and subjected to primerless PCR reactions. Upon several cycles of denaturation, annealing 
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and elongation steps the fragments bound to each other and gradually reassembled to higher 
molecular weight DNA molecules. As a result, from the first 50 cycles of primerless PCR, a clear DNA 
smear was typically detected through DNA electrophoresis and ethidium bromide staining (Fig. 4.5, 
PCR 1). Generally, if the DNA mixture did not reach the required length of 2,3 Kb, 25 additional cycles 
of amplification were performed before progressing to the final amplification (Fig. 4.5, PCR 2). 
 
                            primerless PCR 1                primerless PCR 2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Agarose gel electrophoresis of typical primerless PCR products. Lane 1: 1 kb Invitrogen molecular 
DNA ladder. Lane 2: amplification products after the primerless PCR 1 and 2, respectively. In both cases a clear 
DNA smear is visible. An increase in molecular weight can be noticed through comparison between the 
products of the two subsequent PCRs.   
 
 
The high molecular weight DNA mixture detected on agarose gel revealed a successful reassembling 
process and was then used, at different dilutions, as template for the amplification of the final 
sequences. Couples of external primers carrying target restriction sites for subsequent cloning steps 
have been employed for the amplification. As a result of the final PCR, a DNA product corresponding 
to 2.3 kb was typically detected through DNA electrophoresis and purified from agarose gel (Fig. 4.6).  
Successful amplification of the final full length molecules strictly depended on the quality of the 
templates employed. A specific and clean DNA band of the right size usually appeared when high 
dilutions of the primerless PCR products were employed as templates, reducing the presence of DNA 
not properly assembled in the reaction mixtures. 
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Figure 4.6. Agarose gel electrophoresis of a typical final PCR. Each lane (2-9) represents the product of a single 
PCR reaction performed on a template at increasing dilutions of 1, 1/3, 1/10, 1/30, 1/100, 1/300, 1/1000, 
1/3000 respectively. Lane 1: 1kb DNA ladder. Specific bands are of 2.3 Kb. Unspecific products are visible in the 
first lanes (2 to 6) of the agarose gel .  
 
 
After gel purification the mixture of sequences was digested with appropriate restriction enzymes 
and cloned into a group of recipient DNA entry vectors. Entry vectors are special DNA plasmids 
carrying all the basic elements for selection and plasmid amplification in E.coli (e.g. antibiotic 
resistance, ORI) together with combinations of yeast promoters and terminators (Fig. 4.7). 
 
 
Figure 4.7. Plasmid map of a typical entry vector. The DNA molecules obtained through DNA semi-synthetic 
shuffling were cloned between the restriction sites of HindIII and SacII. Different combination of yeast 
transcription promoters and terminators are present in the different vectors used as recipients. All the 
promoter and terminator combinations of the vectors employed are listed in Table 7.3. 
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After cloning, in order to verify the success of the recombination process in the applied semi-
synthetic shuffling, 60 DNA products were isolated and sequenced.  
Sequence analyses revealed the positive outcome of the method (Fig 4.8). In fact, high numbers of 
recombination events (from 6 to 11) between heterologous DNA “bricks” were detected in each of 
the sequences analysed. Point mutations were significantly reduced (0.08%) due to the absence of 
DNAseI fragmentation step and to the use of proof reading high fidelity DNA polymerases in the 
reassembling process (Zhao and Arnold, 1997). Moreover, fragments from all parental cDNAs were 
represented in the new sequences analysed but contamination with full-length parental sequences 
was never detected. 
From the analysis of the sequences it was noticed that the distribution of the single DNA fragments in 
the chimeric final molecules was not always uniform. In fact, some of the DNA “bricks” seemed to 
occur more frequently than others (Fig. 4.8). This discrepancy in the results with respect to the 
theoretical previsions, was most likely due to slight differences in the amount of fragments during 
the setting of equimolar mixtures for the primerless PCR or to a higher quality of some amplified DNA 
“bricks” that were then preferred in the reassembling process. 
 
 
Figure 4.8. Schematic representation of 10 real DNA sequences (5’-3’) obtained through the application of 
semi-synthetic DNA shuffling to families of triterpenoid synthases cDNAs. Every colour indicates a different 
origin of the fragment. EV42, EV43 and EV48, EV49 are the names for two lupeol synthase and two β-amyrin 
synthase cDNAs, respectively (Table 4.1). 
 
 
Comparison between the recombination regions of chimeric DNA molecules obtained from the 
application of both the random and not random DNA shuffling methods previously described, 
revealed that in almost all the chimera analysed, recombination occurred at the same regions of the 
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sequences, characterized by high homology. This aspect relies on the fact that both methods are 
based on homologous recombination and therefore, regions selected for primers design in the semi-
synthetic shuffling method frequently corresponded to the regions of recombination of the 
sequences obtained through the original DNA family shuffling method. This last aspect added more 
value to the DNA semi-synthetic shuffling method developed in this work, since it efficiently mimics 
the random method but avoiding at the same time the formation of wild type sequences in the final 
mixture. 
Finally, the semi-synthetic method resulted in a highly reproducible, adaptable and efficient protocol 
for the construction of chimeric DNA libraries. Although it does not use random fragmentation due to 
the preselection of the fragments to be recombined, it always leads to the presence of high numbers 
of recombination events in the final sequences.  
The number of predicted products for each group of cDNAs, through application of DNA semi-
synthetic shuffling was 411 (11 fragments and 4 genes per group). The DNA semi-synthetic shuffling 
protocol developed was applied several times to the three groups of triterpenoid synthase cDNAs to 
ensure the highest representation of different chimeric molecules in the final mixture prior to 
proceed with subsequent experimental steps. Based on recombination, cloning and transformation 
efficiency, the size of the chimeric cDNA library into different entry vectors was roughly estimated to 
be between 8 and 9 million of sequences.  
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eYACs construction  
In this chapter the investigation of a multi-cloning system based on expressible yeast artificial chromosome 
(eYACs) is described. This technology, developed at Evolva SA, allows for the simultaneous expression of a large 
number of genes in the yeast Saccharomyces cerevisiae and represents a powerful method for the 
reconstruction of complex biosynthetic pathways in this host organism. Here, the eYACs were assembled with 
expression cassettes of cDNA molecules essential to reconstitute the biosynthetic pathway of plant 
triterpenoids. 
 
 
In order to simultaneously express high numbers of chimeric and parental triterpenoid synthase 
cDNAs in yeast, expressible yeast artificial chromosomes (eYACs) were used. eYACs are powerful 
tools for multiple cloning and expression of heterologous genes in yeast and for reconstruction of 
exogenous or new biosynthetic pathways. 
In this work eYACs were aimed to be employed for the coordinate and controllable expression of 
high numbers of triterpenoid synthase enzymes that are potentially able to enzymatically act on 2,3 
epoxy-squalene converting it into different triterpenoid backbones. Part of the cDNA library 
previously prepared was therefore used for construction of eYACs. The mixture of entry vectors 
carrying chimeric and parental cDNAs has been purified from E.coli and processed with NotI and AscI 
restriction enzymes. After digestion, the two main fragments, expression cassette and vector 
backbone respectively, were released together with two “stopper” DNA fragments (Fig. 4.9). 
Restriction with AscI and NotI liberated the expression cassettes and the vector backbones with 
incompatible sticky ends. Before proceeding with the expression cassettes concatenation and in 
order to ensure a successful ligation of the cassettes, the “stopper” fragments were sequestered 
away by adding short competitive oligonucleotides to the mixture (Fig. 4.9). Through denaturation 
and fast cooling steps, the competitive oligonucleotides added formed a dsDNA with the 
complementary strand of the stopper fragments, preventing their renaturation. This process allowed 
for the formation of new double short blunt ends DNA strands that could not participate to the 
concatenation process (Fig. 4.9). After this step the DNA mixture consisted of vector backbones with 
NotI sticky ends, expression cassettes with AscI sticky ends, and short dsDNA fragments with blunt 
ends.  
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Figure 4.9. Steps involved in the preparation of the expression cassettes for the concatenation reaction. The 
short stopper fragments if kept in the mixture could impair the concatenation process. Synthetic competitive 
oligonucleotides are ssDNA able to efficiently bind one strand of the stopper fragments and create dsDNA with 
blunt ends that cannot participate to the concatenation process. 
 
 
The expression cassettes were randomly concatenated by a standard ligation process into long chains 
of high molecular weight DNA (Fig. 4.10b). Subsequently chromosome arms carrying yeast elements 
for stability, duplication and segregation of the chromosomes were added to the ends of the DNA 
concatamers to create linear eYAC molecules (Fig. 4.10c). The mixture was then transformed into 
yeast spheroplasts of strain EYS1019 (genotype in Table 8.1). The presence of two different 
auxotrophic markers in the telomeres and in the internal part of the chromosomes, respectively, 
allowed an efficient selection of colonies that stably maintained the artificial chromosomes after 
several generations (Fig. 4.10d).  
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Figure 4.10. Schematic representation of eYACs assembly. a) Expression cassettes of cDNAs and genes of 
interest in the recipient entry vectors. b) Digestion process releases all the expression cassettes with 
compatible sticky ends (process described more in detail in figure 4.9). c) Random concatenation of the 
expression cassettes in high molecular weight DNA and subsequent chromosome arms (brown) addition to the 
ligation mixture. The arms carry all the elements for the functionality and stability of the chromosomes; 
centromere (circle), telomeres, and the autonomous replicating sequence (not shown). In addition, they carry 
an expression cassette for auxotrophic selection marker (LEU2). d) Arms are ligated to the ends of the cassettes 
concatamers. 
 
 
According to the original protocol, the expected eYACs average size was 130 Kb corresponding to 
approximatively 45 expression cassettes (  ̴2.9 Kb) per chromosome (Naesby et al., 2009).  
During eYACs preparation many aspects of the method have been carefully evaluated in order to 
ensure the best results. For example, self-recombination events due to high similarity of the 
sequences used in the construction strongly influenced the favourable outcome of the experiments. 
In fact, preparations performed exclusively using libraries of chimeric and parental triterpenoid 
synthase cDNAs did not produce any functional eYAC and consequently no colonies were detected 
on selection plates after transformation. To overcome this technical problem, additional eYACs 
preparations were performed trying to dilute the presence of high similarity sequences in the 
mixture by adding in different amounts of foreign DNA material, not relevant for expression in yeast 
and appropriately prepared to be concatenated as connectors between the main expression 
cassettes. The addition of external DNA material during eYACs assembly decreased the number of 
chimeric and parental triterpenoid synthase expression cassettes per chromosome since the final 
average size of the chromosomes was not expected to change. This procedure led to a successful 
a.     b. 
c. 
d. 
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concatenation process and created more stable eYACs with respect to the previous trials. With the 
optimized protocol few hundreds of yeast colonies containing randomly assembled eYACs resulted 
from each transformation. In order to estimate the quality and content of the chromosomes, 
approximately 20 positive colonies were selected and grown in liquid medium. The organic phases 
were extracted and finally analysed through GC-MS for detection of  triterpenoid molecules. Despite 
the ability of the cells to grow on double selection media suggested for the presence of eYACs, no 
detection of known triterpenoids was revealed through GC-MS in any of the samples analysed. The 
negative outcome was addressed, with high probability, to the short nature of the chromosomes due 
to residual self-recombination processes and to the presence of the non-functional DNA material 
that provided more stability to the final concatamers but at the same time significantly reduced the 
number of functional expression cassettes represented per chromosome.  
In order to investigate whether the absence of triterpenoids production in the yeast harbouring the 
eYACs could be also due to the impaired functionality of the triterpenoid synthases (natural and 
chimeric), four parental β-amyrin syntases cDNAs (Accession Numbers: AB037203, AB009030, 
AF478453, AB014057) and twenty chimeric sequences were individually sub-cloned and expressed in 
yeast strain EYS1019. After cultivation in inducible media in order to trigger the expression of the 
cDNAs cloned downstream the GAL1 promoter, 5 ml of each culture were processed through an 
ethanol/hexane extraction procedure and the organic phases were analysed by GC-MS. 
Saccharomyces cerevisiae wild type cells contain ergosterol, synthetized from 2,3 epoxy-squalene via 
lanosterol, as a major sterol component but do not produce structures similar to the β-amyrin. For 
this reason plant triterpenoids can be easily detected in GC profiles of yeast extract. 
Yeast cells that heterologously expressed β-amyrin synthases of Glycyrrhiza glabra (AB037203) and 
Panax ginseng (AB009030) accumulated a detectable compound with a mass spectral fragmentation 
pattern identical to the standard β-amyrin (Fig. 4.11). The areas of the two β-amyrin peaks detected 
indicated a strong difference in the activity of the two wild type synthases when expressed in yeast.  
The cells expressing β-amyrin synthases of Medicago truncatula (AF478453) and Panax ginseng 
(AB014057) did not produce any detectable known triterpenoid despite the fact that their 
functionality in yeast was already demonstrated in the past (Kushiro et al., 1998; Iturbe-Ormaetxe et 
al., 2003).  
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Figure 4.11. a) GC-MS profiles of EYS1019 yeast strain expressing β-amyrin synthases from Glycyrrhiza glabra 
(orange) and Panax ginseng (blue). The peak corresponding to β-amyrin was detected at 16.67 minutes of 
retention time. As negative control the strain was transformed with the empty plasmid and after cultivation in 
galactose selection medium the organic extract was analysed (purple). b) Mass spectrum of the detected peak 
(upper panel) compared with the mass spectrum of standard β-amyrin (lower panel). 
 
 
The GC-MS analyses of yeast cells expressing wild type synthases were followed by the analyses of 
yeast expressing for chimeric sequences obtained through the DNA semi-synthetic shuffling. GC-MS 
confirmed that three of the chimeric enzymes tested produced β-amyrin with different efficiencies 
respect to the wild type parental enzymes (Fig. 4.12). These results strongly suggested that the DNA 
mutagenesis method developed in this work leads to functional enzymes with modified catalytic 
efficiencies and confirmed the good quality of the cDNA library previously constructed.  
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Figure 4.12. a) GC-MS profiles of EYS1019 yeast strain expressing chimeric enzymes, obtained through DNA 
semi-synthetic shuffling (red, green, orange), and the β-amyrin synthase from Panax ginseng (blue). A peak 
corresponding to β-amyrin was detected at 16.67 minutes of retention time. As negative control, the strain was 
transformed with the empty plasmid and the extract analysed after cultivation in galactose (purple). b) Mass 
spectrum of one of the detected peaks (upper panel) compared with the mass spectrum of standard β-amyrin 
(lower panel). 
 
 
Different catalytic features such as product specificity, associated with the new chimeric enzymes 
expressed in yeast, were neither demonstrated nor excluded. In fact, the GC-MS method applied, 
although was optimal for detection of triterpenoid backbones, did not guarantee a wide screening of 
chemical scaffolds. Therefore eventual new products, due to the reactions catalysed by the chimeric 
enzymes, with different structures with respect to the triterpenoid could not be detected. For this 
last purpose much more advanced analytical analyses and strategies would be needed.  
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Yeast-based 11β-HSD1 assays 
Finalization of this innovative strategy for intracellular production and screening of 11β-HSD1 inhibitors 
involved the development of cellular systems where the functionality of the target enzyme is connected with an 
output easy to be detected. Yeast cells in the synthetic biology platform here investigated are meant to be first, 
generator of compounds and second, screening systems for the activities of these compounds against the target 
enzyme (Klein et al. 2014). For this purpose this chapter describes the construction of two yeast strains, RVY97 
and RVY102, for screening of 11β-HSD1 inhibitors.  
 
 
Yeast has emerged in the last decades as a powerful organism for the study of many human target 
enzymes. The deep genetic information available on this system has allowed it to become an 
increasingly popular model for pharmacological and drug discovery studies that can be used to 
analyse the effects of drugs in vivo during initial stages, before tests are performed in mammalian 
systems. Compared to higher eukaryotes, yeast cells are more economical, easier to grow and can be 
genetically manipulated with greater ease. Hence, the availability of well-established genomic 
methods and resources makes the budding yeast an extremely valuable asset for the screening of 
molecules with possible pharmaceutical applications (Barberis et al., 2005). Moreover, coupled with 
technologies that allow the construction of complex biosynthetic pathways yeast cells represent 
important tools for simultaneous synthesis and screening of heterogeneous compounds with 
therapeutic features. 
 
 
Construction and validation of the assay strain RVY97 
In this study the assay strain RVY97 was conceived in order to have a direct connection between the 
activity of 11β-HSD1 and a fluorescent output. The human 11β-HSD1 enzyme, expressed in yeast 
cells, reduces the cortisone provided in the growth medium, thereby converting it to cortisol, the 
active form of the steroid hormone. Cortisol binds to the glucocorticoid receptor (GR), also 
heterologously expressed in yeast. The active complex translocates into the nucleus, promoting the 
expression of yEGFP via specific interaction with the glucocorticoid response element (GRE) 
upstream of the reporter gene. In this strain inhibition of 11β-HSD1 causes a decrease of the green 
fluorescence (Fig. 4.13). 
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Figure 4.13. Schematic representation of the screening strain RVY97. In strain RVY97 the cortisone provided in 
the growth medium is converted to cortisol inside the cell by the enzyme 11β-HSD1. Cortisol binds the GR 
inducing assembly of an active complex that translocates to the nucleus. Through binding of the complex to the 
GRE, expression of the yEGFP reporter protein is triggered. In the presence of 11β-HSD1 inhibitors, cortisol is 
not produced, the GR is inactive and yEGFP not expressed. 
 
 
The yEGFP reporter gene was placed under the control of 3xGRE+CYC1-TATA promoter that upon 
binding of the murine glucocorticoid receptor efficiently activates a downstream reporter constructs 
in yeast (Picard et al., 1990). The promoter 3xGRE+CYC1-TATA included the insertion at position -178 
of the truncated yeast CYC1 promoter of three tandem 26-bp oligonucleotides derived from the 
murine tyrosine aminotransferase GRE (Garabedian and Yamamoto, 1992). The construct was 
integrated as a single copy into the ECM3 locus of chromosome XV of the S1502B yeast strain 
genome. The mouse cDNA Nr3c1 codifying for the glucocorticoid receptor (GR) was cloned into a 2μ 
vector under the control of the GAL1 promoter and transformed in the S150-2B strain containing the 
integrated GRE-yEGFP construct. The resulting yeast strain was named as RVY96. 
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To assess the functionality of the fluorescent reporter construct, yEGFP expression experiments were 
performed with strain RVY96 in presence of glucocorticoids.  
Cortisol or dexamethasone, able to bind efficiently to the glucocorticoid receptor, were added to 
yeast cultures and the expression of yEGFP within the RVY96 yeast population was monitored 
through fluorescence microscopy. The cooperation between the GR and the GRE-yEGFP in the RVY96 
strain was confirmed. Dexamethasone treatments significantly triggered the expression of yEGFP in 
the population and on the contrary no fluorescence was detected in the control samples in which the 
cells were treated with DMSO (Fig. 4.14). 
 
 
 
Figure 4.14. Effect of dexamethasone on yEGFP expression in RVY96 yeast strain. DMSO (control) and 800 μM 
dexamethasone (DXM) were added to the cell cultures. yEGFP expression was detected in the population 
treated with dexamethasone and not in cells treated with DMSO. The analyses were carried out 6 hours after 
the addition of DMSO and dexamethasone, respectively. 
 
 
In order to finalize the construction of the assay strain RVY97, the human cDNA HSD11B1, codifying 
for the enzyme 11β-HSD1, was cloned under the control of the GAL1 promoter into a 2μ vector and 
transformed into the strain RVY96. GAL1 allowed a fine and simultaneous expression of 11β-HSD1 
together with the mouse GR in the resultant RVY97 strain and guaranteed functional collaboration of 
the two mammalian proteins for the final transactivation of the fluorescent reporter. The expression 
of 11β-HSD1 in the RVY97 was confirmed through western blot analyses and the activity of the 
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enzyme expressed in yeast was investigated both in vitro (after enzyme purification) and in vivo 
through HPLC analyses of organic extracts from yeast cultures treated with cortisone (Manday 
Viswanathan P. master thesis).  
In order to investigate for the functionality of the strain RVY97, FACS analyses were used to assay the 
expression of yEGFP as response to the treatment with different cortisone concentrations, ranging 
from 1.95 μM to 2000 μM (Fig. 4.15a). As expected, green fluorescence in the treated population 
increased, due to the action of 11β-HSD1, with increasing concentrations of cortisone, whereas in the 
absence of hormone no fluorescent signal was detected. Concentration of cortisone as low as 31.5 
μM were effective, leading to appearance of an unambiguous fluorescent signal connected to the 
activity of 11β-HSD1. However, higher concentrations of cortisone were more desirable due to the 
stronger induction of reporter protein expression. Expression of yEGFP, driven by 11β-HSD1-
dependent conversion of cortisone to cortisol, rose significantly upon treatment with a range of 
cortisone concentrations between 60 and 500 μM. At higher concentrations a plateau of 
fluorescence intensity was reached (Fig. 4.15a). Of all hormone concentrations tested, 250 μM 
cortisone guaranteed the best compromise between intensity of the generated fluorescent signal, 
solubility and low toxicity of cortisone added to the yeast population. FACS analysis and fluorescence 
microscope images of RVY97 cells treated with DMSO (control) and 250 μM cortisone are shown in 
figure 4.15, b and c, respectively. These results suggest the dependency of the fluorescent signal on 
the activity of 11β-HSD1 on cortisone. In this strain the identification of putative inhibitors of the 
target enzyme is based on the loss of fluorescence in the treated cells. The specificity of the signal 
upon treatment with cortisone was confirmed with a strain in which the plasmid carrying the 11β-
HSD1 expression cassette has been replaced by the equivalent empty plasmid. No response to 
cortisone was detected in the negative control strain. 
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a.  
 
 
 
 
 
 
 
 
 
 
b.                      c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. Effect of cortisone on yEGFP expression in yeast strain RVY97. a) Increased cortisone 
concentrations led to an increase of yEGFP expression in a concentration dependent manner. The treated 
RVY97 population (10’000 events) was analysed by FACS and the results are expressed in percentage of RVY97 
cells showing yEGFP fluorescence. b) Fluorescence microscopy of strain RVY97 showed that cortisone treated 
cells displayed a strong fluorescent response to the hormone. c) FACS analysis of the strain RVY97 cultivated 
with DMSO (upper panel) and 250 μM cortisone (lower panel) enabled quantitative analysis of the hormone 
response of this specific strain. The gate highlights the RVY97 population positive for the yEGFP expression. All 
analyses were carried out 6 hours after the addition of DMSO and cortisone, respectively. 
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To address the validity of the assay for screening of putative 11β-HSD1 inhibitors, a series of 
experiments with a synthetic inhibitor of this enzyme were performed. RVY97 strain was incubated 
with cortisone in presence of carbenoxolone (CBX), a synthetic hemisuccinyl ester derivative of 
glycyrrhetinic acid. Carbenoxolone has been shown to exert potent but non-selective 11β-HSD1 
inhibitory activity and is frequently used as control in inhibition studies involving this target enzyme 
(Monder et al., 1989) Carbenoxolone behaves as a competitor of cortisone, binding to the active 
domain of 11β-HSD1 (Castro et al., 2007; Su et al., 2008). 
In order to validate the assay with this molecule, different inhibitor concentrations ranging from 0.1 
to 3 μM were added to 1 million RVY97 cells together with 250 μM of cortisone. Increasing 
concentrations of carbenoxolone caused a gradual loss of yEGFP expression, indicating a decreased 
activity of 11β-HSD1 in the population with a complete absence of fluorescence at a concentration of 
3 μM of inhibitor, most probably associated with the complete inhibition of the enzyme (Fig. 4.16).  
 
 
Figure 4.16. Effect of carbenoxolone (CBX) on 11β-HSD1 dependent response in the strains RVY97. 11β-HSD1 
dependent yEGFP fluorescence of strain RVY97 treated with 250 μM cortisone and increasing CBX 
concentrations. Increasing concentration of carbenoxolone (up to 3 μM) led to a decreasing green fluorescence 
in the yeast population indicating a progressive inhibition of 11β-HSD1. The fluorescence of untreated cells (No 
CBX) was set at 1. 
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Construction and validation of the assay strain RVY102  
A robust cell-based screening assay relies on the strong correlation between an intracellular event 
and a univocal and easily detectable output. Screening systems with a positive readout guarantee the 
selection of hits from the analysis of large number of samples with minimum false positive results 
caused by unrelated intracellular events, such as impaired cellular viability or loss of an element of 
the assay system. To set up a more reliable assay for the screening of 11β-HSD1 inhibitors a strain 
was constructed in which inhibition of 11β-HSD1 is connected to a positive fluorescent readout. In 
contrast to strain RVY97 where the activity of the enzyme is directly connected with the expression 
of a fluorescent reporter protein, in strain RVY102 the reduction of cortisone, driven by 11β-HSD1, is 
combined with a TEV protease induced protein instability (TIPI) mechanism (Taxis et al., 2009) (Fig. 
4.17a). This mechanism reversely combines the activity of the target enzyme to the stability of a 
constitutively expressed reporter protein. The TIPI strategy exploits the presence of a TEV cleavage 
site in a reporter protein, in order to induce its degradation. 
The reporter construct expresses a fluorescent fusion protein consisting of the red tandem dimer (td) 
Tomato, the TEV recognition site, an N-Degron destabilizing sequence, the SF3b155381-424 protein 
domain and the yEGFP (Taxis et al., 2009) (Fig. 4.17b). 
As shown in figure 4.17a, the expression of the TEV protease under control of the glucocorticoid 
response element is driven by the active complex formed after specific binding of cortisol to the 
glucocorticoid receptor. Expression of the TEV protease, leads to cleavage of the reporter protein 
and to the exposure of a dormant N-Degron sequence. This sequence contains at its N-terminus the 
destabilizing amino acid phenylalanine followed by several lysine residues that, when exposed, serve 
as attachment sites for ubiquitin leading the protein to proteosomal degradation (Fig. 4.17b). The 
exposure of this destabilizing stretch of amino acids, after TEV protease cleavage, causes the C-
terminal part of the reporter construct, including yEGFP, to undergo degradation (Bachmair et al., 
1986). The SF3b155381-424 protein domain binds strongly to the protein p14, fused to TEV, thus 
enhancing processivity of the protease (Taxis et al. 2009). The tdTomato red fluorescent protein is 
used for normalization purposes, since it does not undergo degradation upon TEV protease activity. 
On the other hand, the yEGFP reporter protein reversely monitors the TEV protease activity, as it is 
degraded upon TEV expression.  
The described cascade in strain RVY102 directly couples the activity of 11β-HSD1 to yEGFP 
degradation. Inactivation of 11β-HSD1 caused by inhibitors, leads to stability of the reporter protein 
and detection of an intact green fluorescent signal in the population. 
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a.  
 
b. 
 
 
Figure 4.17.  a) Schematic representation of the screening system RVY102. Cortisone added to the growth 
medium enters RVY102 cells and is reduced to cortisol by the enzyme 11β-HSD1. The active complex formed by 
binding of cortisol to GR triggers expression of the TEV protease which binds to its cleavage site and cuts the 
reporter fluorescent protein that then undergoes degradation. Presence of an 11β-HSD1 inhibitor will stabilize 
the reporter protein. b) Graphic representation of the reporter fusion protein expressed in strain RVY102. The 
fusion protein consists of the red tandem dimer (td) Tomato, the TEV recognition site, an N-Degron 
destabilizing sequence, the SF3b155
381-424 
protein domain and the yeast enhanced green fluorescent protein 
(yEGFP). Once expressed, the TEV protease cuts at its cleavage site on the reporter protein, leading to exposure 
of the N-Degron sequence and degradation of yEGFP. The TEV recognition sequence and the destabilizing 
amino acid (phenylalanine) are shown.  
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In order to construct the yeast strain RVY102, first, the TEV protease gene was cloned under the 
control of the promoter 3xGRE+CYC1-TATA and the construct was integrated into the ECM3 locus of 
chromosome XV of the S150-2B yeast genome. After, the N-Degron fluorescent reporter construct 
controlled by GAL1 promoter was integrated at the KIN1 locus of chromosome IV, and its expression 
confirmed through fluorescence microscopy of cells grown in galactose medium. 
Furthermore, the Nr3c1 expression construct, codifying for GR, was transformed and the resultant 
yeast strain, containing all the three elements, was named as RVY101. The functional cooperation 
between the GR, GRE-TEV, and N-Degron fluorescent protein was tested in RVY101 upon treatment 
with dexamethasone. The synthetic glucocorticoid, able to bind and induce translocation of the GR 
into the nucleus, triggered the expression of TEV and as consequence degradation of yEGFP. As 
expected tdTandem tomato fluorescence did not changed upon hormone treatment (data not 
shown).  
Once the appropriate response of the strain RVY101 to dexamethasone was confirmed, in order to 
complete the construction of the assay strain RVY102, the expression vector carrying the construct 
GAL1-HSD11B1 was transformed in RVY101. As previously confirmed in the strain RVY97, the GAL1 
promoter allowed a fine and simultaneous expression of the 11β-HSD1 together with GR and a 
constant expression of the N-Degron fluorescent reporter protein.  
Functionality of the assay strain RVY102 was tested by FACS analyses. The green fluorescence 
response was monitored at different time points upon addition of different cortisone concentrations 
(from 125 μM to 2000 μM) (Fig. 4.18a). As expected, treatments with increasing concentrations of 
cortisone caused a gradual loss of yEGFP after 6 and 9 hours of incubation, indicating the reduction 
of cortisone to cortisol driven by 11β-HSD1 and the consequent expression of TEV protease. 
Conversely, cells treated with DMSO maintained stable expression levels of the fluorescent fusion 
protein. Significant yEGFP degradation was already observed upon 6 hours of treatment with 1000 
and 2000 μM of cortisone and degradation further increased upon 9 hours of incubation (Fig. 4.18a). 
Fluorescence microscopy and FACS measurements also showed the decrease in yEGFP signal, 
denoting a loss of green fluorescence upon cortisone treatment whereas td-Tomato fluorescence 
remained constant (Fig. 4.18, b and c).  
To select for the best experimental conditions many factors including cortisone solubility and toxicity, 
time of incubation, and fluorescent response were experimentally evaluated. Finally, 6 hours of 
incubation with 1000 μM cortisone were employed for the validation of strain RVY102.   
The specificity of the signal upon treatment with cortisone was confirmed with a strain in which the 
plasmid, carrying the 11β-HSD1 expression cassette, has been replaced by the equivalent empty 
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plasmid. The strain was, except for the missing 11β-HSD1 expression construct, identical to the 
parental assay strain RVY102. No response to cortisone was detected in the control strain. 
 
a. 
 
 
 
 
 
 
 
  
b.                                                                                 c. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.18. Effect of cortisone on the yEGFP degradation in yeast strain RVY102. a) Increased cortisone 
concentrations caused the expression of the TEV protease in a time and concentration dependent manner. The 
TEV protease acted on the reporter protein construct causing degradation of the yEGFP. At all-time points 
tested the yEGFP degradation signal in the cortisone-treated cells was significant with respect to the signal of 
the negative control cells treated with DMSO. b) RVY102 yeast population treated with DMSO and 1000 μM 
cortisone. Pictures acquired 6 hours upon initiation of the treatment with cortisone showed degradation of 
yEGFP in part of the population (iii), while the tdTomato signal remained constant in both treated and 
untreated cells (ii). c) FACS analysis of RVY102 strain treated for 6 hours with DMSO (upper panel) and 1000 μM 
cortisone (lower panel). Cells that show yEGFP degradation are gated. 
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In order to validate the yeast strain RVY102 for screening of putative 11β-HSD1 inhibitors, 
carbenoxolone concentrations ranging from 0.1 to 3 μM were added to 1 million RVY102 cells 
together with 1000 μM cortisone. FACS analyses revealed that increasing concentrations of 
carbenoxolone gradually led to an increase of the reporter protein in the population. At a 
concentration of 3 μM carbenoxolone almost no degradation of yEGFP was detected suggesting 
complete inhibition of the enzyme 11β-HSD1 (Fig. 4.19).  
 
 
Figure 4.19. 11β-HSD1 dependent yEGFP fluorescence of strain RVY102 treated with 1000 μM cortisone and 
increasing CBX concentrations. Increasing concentration of carbenoxolone improved the stability of yEGFP in 
the yeast population indicating a progressive loss of enzyme activity. Cells treated with 1000 μM cortisone and 
3 μM carbenoxolone showed a fluorescence comparable to the one of the untreated population (DMSO) 
indicating a complete absence of yEGFP degradation.  tdTomato fluorescence was maximum and constant in all 
samples analysed and was not affected by treatments with cortisone and carbenoxolone. For data 
normalization details see “Experimental procedures”.  
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Improving the sensitivity of the assay systems by inhibiting Pdr5p 
The relatively high concentration of cortisone required to trigger the yeast based assays, when 
compared to the concentration of carbenoxolone needed to completely inhibit 11β-HSD1 raised the 
question whether the influx of cortisone might be limited, and therefore intracellularly the cortisone 
concentration is much lower than expected. Consequently, the intracellular availability of cortisone 
was investigated.  
Previous studies demonstrated that in yeast, a low accumulation of certain steroid molecules due to 
the action of membrane-embedded drug-efflux pumps, can strongly affect the functionality of an 
intracellular cascade driven by the heterologous GR-hormone complex (Wright et al., 1990; Kralli et 
al., 1995). In the yeast Saccharomyces cerevisiae, an ATP-binding cassette (ABC) transporter, Pdr5p, is 
able to decrease accumulation of certain steroids, thus changing cellular responses caused by GR-
ligand complexes. Pdr5p has many different steroid and non-steroid substrates and tends to protect 
the cells from an improper accumulation of undesired molecules (Mahé et al., 1996; Kolaczkowski et 
al., 1996; Rogers et al., 2001). The null mutants of this transporter allow accumulation of 
glucocorticoids in cells and maximal activation of the heterologous GR. There is evidence that 
dexamethasone, a synthetic equivalent of cortisol, is an important substrate of the transporter Pdr5p 
(Kralli et al., 1995). Therefore, a possible recognition and excretion of cortisone by Pdr5p was 
investigated. The expression and activity of Pdr5p in strains RVY97 and RVY102, respectively, was 
studied upon treatment with 5 μM Rhodamine 6G, a well-known target of Pdr5p (Kolaczkowski et al. 
1996). Through accumulation of this specific dye within yeast cells, it is possible to get indications 
about the activity of this transporter. To confirm that accumulation of Rhodamine 6G is limited due 
to Pdr5p activity, the Pdr5p inhibitor FK506 (Kralli et al., 1996) was added to the cells leading to a 
strong intracellular accumulation of the dye (Fig. 4.19). Those experiments demonstrated the 
presence of significant amounts of active transporter molecules Pdr5p in the assay strains. 
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                   a.                            b. 
 
Figure 4.20. Rhodamine 6G accumulates in the cells upon Pdr5p inhibition. Rhodamine 6G accumulation in a) 
RVY97- and b) RVY102- yeast strains treated or not treated with 10 μg/ml FK506, a known inhibitor of Pdr5p. 
 
 
Next, the green fluorescent output of strains RVY97 and RVY102 was examined in the presence of 10 
μg/ml FK506 and upon treatment with different concentrations of cortisone. Addition of FK506 
dramatically improved the sensitivity of the assay strains to cortisone. In fact, hormone 
concentrations up to 60 times lower than used before caused equivalent responses of the RVY97 and 
RVY102, when the Pdr5p transporter was not active (Fig. 4.20). These results strongly suggested that 
cortisone is a substrate of the Pdr5p transporter.  
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a.       
   
                   b.        
    
 
Figure 4.21. Effects of FK506 on RVY97 and RVY102 assays functionality. Both a) RVY97 and b) RVY102 assays 
have been tested with or without FK506 at different concentrations of cortisone. In both assays an increased 
sensitivity to cortisone in presence of the Pdr5p inhibitor is shown. Each experiment was performed at least 
three independent times with similar results. The figure represents a single result of the replicates. 
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Intracellular glucocorticoid levels play a relevant role in the pathogenesis of metabolic diseases such 
as obesity and metabolic syndrome. Moreover, in the last years, high levels of active glucocorticoids 
in skin have been associated with impaired collagen metabolism and reduced wound healing 
processes in diabetic and elderly individuals.  Therefore, inhibitors of 11β-HSD1, the main enzyme 
responsible for the activation of glucocorticoids at intracellular level, have been proposed as crucial 
compounds for the treatment of these conditions and for development of skin care products that 
regulate skin homeostasis. Many strategies to find specific inhibitors for this enzyme have been 
developed, but only a few molecules have been identified. Among other reasons, this might be due 
to the fact that the screening of large libraries of small molecules and the identification of 
pharmaceutically active candidates need very efficient assay systems, often difficult to establish, or 
whose development is very cost- and labour intense. 
The research work presented in this thesis casts the first stone for the realization of a new approach 
for synthesis and screening of inhibitors of the human enzyme 11β-HSD1. The original idea was born 
from collaboration with an industrial partner, Evolva SA, and intends to use yeast cells in order to 
identify new specific compounds for the pharmacological inhibition of the isozyme 11β-HSD1, 
exploiting Evolva SA’s Synthetic Biology Technology Platform. This platform couples combinatorial 
expression of multiple genes, from plant or other organisms, in the yeast Saccharomyces cerevisiae 
with screening systems that can identify compounds with the desired properties. 
In order to reach the final step of production and screening of compounds, this work experimentally 
investigated the fundamental aspects for the success of the entire strategy. 
 
Triterpenoids are a large class of natural secondary metabolites mainly represented in plants. Due to 
their well-known positive effects on human health they are often used as a source for compounds 
with pharmaceutical applications. Moreover, components of this family are known to exert inhibitory 
effects against the human enzyme 11β-HSD1, but in some cases, due to their low selectivity towards 
the 11β-HSDs, they cannot be intensively used for treatments.  
Since triterpenoids represent a promising source of new inhibitors of 11β-HSD1, this study aimed at 
the reconstruction of their biosynthetic pathway in yeast through expression of different classes of 
natural triterpenoid synthases. Moreover, additional genetic information, in order to provide new 
enzymatic activities and to further increase the chemical scaffold diversity synthetized in yeast, were 
generated by gene shuffling procedures, applied to groups of triterpenoid synthase cDNAs. Among 
many methods for random mutagenesis, two DNA family shuffling protocols were selected for the 
construction of the final library. The original DNA family shuffling method developed by Crameri and 
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colleagues in 1998, was successfully adapted and applied. Nevertheless low numbers of 
recombination events, high percentages of random point mutations and strong presence of wild-type 
parental sequences were usually detected in the final mixture of molecules.  
The Synthetic Biology Technology Platform investigated here intends to use a multiple cloning 
strategy for simultaneous expression of the new genes in yeast in order to screen for compounds 
with 11β-HSD1 inhibitory activity. The strong presence of unmodified triterpenoid synthase cDNAs 
obtained from the application of the original DNA family shuffling method could dramatically lower 
the number of chimeric sequences represented in the assembled expressible yeast artificial 
chromosomes. In order to guarantee a higher presence of mutant triterpenoid cyclase cDNAs and to 
reduce the contamination with parental unmodified cDNAs, a new DNA family shuffling method, 
defined as semi-synthetic, was developed. Although this method did not provide a random 
fragmentation of sequences, it guaranteed a highly efficient recombination process during the 
primerless PCR. Results in fact demonstrated the absence of parental non-modified genes and 
constant high numbers of recombination events in the final mixture of sequences. Through this 
method a large library of about 8-9 millions of new sequences, potentially codifying for chimeric 
triterpenoid synthases, was constructed.  
The library of chimeric DNA sequences assembled during the first part of the work as well as a library 
of parental triterpenoid synthase cDNAs were employed for construction of eYAC molecules. eYACs 
were assembled with the genetic information that provided the yeast with the missing functions for 
the synthesis of plant triterpenoids. The expression of natural triterpenoid synthases aimed at 
creating natural triterpenoid scaffolds that represent an important source of pharmaceutical active 
compounds. In addition, the simultaneous expression of large numbers of chimeric triterpenoid 
synthases aimed at providing more chemical variability among the synthetized molecules. The eYACs 
construction protocol originally conceived at Evolva SA, was adapted and applied to the purposes of 
this work in order to reach the best outcome. However, due to the significant presence of similar 
sequences in the DNA mixture employed for preparation of the chromosomes, spontaneous 
recombination processes caused instability of the final molecules. To overcome this problem, 
different concentrations of non-functional exogenous DNA were added to the mixture of triterpenoid 
synthase expression cassettes. The external DNA material diluted the concentration of similar 
sequences involved in the concatenation, providing higher stability to the chromosomes. eYACs were 
successfully transformed in yeast in order to study the production of triterpenoids and to test for the 
expression and functionality of the synthases. After appropriate cultivation, the organic extracts of 
yeast populations carrying eYACs were analysed through GC-MS and no naturally occurring 
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triterpenoid molecules were detected in any of the samples. This result could be due to the impaired 
expression or functionality of the wild type triterpenoid synthases yielding a production level below 
the limit of detection.  
In order to investigate the functionality of parental and chimeric triterpenoid synthases, a group of 
parental β-amyrin synthases and twenty chimeric triterpenoid synthases were individually expressed 
in yeast and the organic extracts were analysed through GC-MS. The expression of two of four 
parental β-amyrin synthases led to detectable production of β-amyrin. Moreover, functionality was 
confirmed for three of the twenty chimeric enzymes expressed. These data therefore suggested that 
most likely the absence of detectable triterpenoids in the yeast carrying eYACs was due to the short 
size of the chromosomes representing only a limited number of expression cassettes and not to the 
impaired functionality of the enzymes expressed. Nevertheless a wider screening of yeast clones 
carrying eYACs would be necessary to confirm this assumption.  
CG-MS analyses generally provide a useful strategy for triterpenoid detection in yeast. However the 
method applied, alone, was not advanced enough to screen for new chemical scaffolds produced by 
the activity of chimeric enzymes. In fact, since no predictions could be made on the possible 
structures to be detected, more complex approaches such as differential analysis, liquid 
chromatography-mass spectrometry, derivatization of compounds etc., would be needed. 
In future, the stability and the quality of the eYACs will be certainly increased by adding a library of 
cDNAs codifying for decorating enzymes such as glycosyltransferases, sulfotransferases, 
transaminases, acyl-transferases and cytochrome P450 oxygenases, currently under construction at 
Evolva, to the other genetic information used for the construction of the chromosomes. These 
additional cDNAs will replace the non-functional DNA used during this work to dilute the 
concentration of similar sequences in the eYACs and will also provide new genetic information for 
classes of enzymes that can add modifications to the chemical scaffolds, most likely leading to a 
dramatic increase of the chemical diversity synthetized. 
Production of natural and new chemical scaffolds by the yeast cells carrying the new assembled 
chromosomes will be directly screened through in vivo assays for the identification of molecules with 
inhibitory activity towards 11β-HSD1.  
In order to develop functional yeast-based assays for screening of molecules with 11β-HSD1 
inhibitory activity, many efforts were dedicated during the work to the construction and validation of 
two yeast strains. Both strains, RVY97 and RVY102 functionally connect the reductase activity of the 
human enzyme to a fluorescent output. The two assay-systems were successfully tested and 
functionally evaluated upon treatments with different cortisone concentrations. The specificity of the 
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fluorescent response was demonstrated through development of negative control strains identical to 
the originals but lacking the 11β-HSD1 construct, which did not respond to cortisone treatments. 
Moreover, the assays have been validated using carbenoxolone, one of the most widely used 11β-
HSD1 inhibitors. The results demonstrated a clear connection of the fluorescent outputs with the 
reductase activity of the 11β-HSD1 enzyme. Increasing carbenoxolone concentrations caused 
changes in the fluorescent signal of both strains indicating inhibition of 11β-HSD1 and the results 
were reproducible and comparable between the two independent strains. Finally, the sensitivity of 
the yeast based assays to cortisone was significantly improved through inhibition of the yeast 
multidrug transporter Pdr5p. Cortisone was demonstrated to be an effective substrate of this efflux 
pump that usually prevents its accumulation at intracellular level. 
The developed yeast strains will be used for transformation of new eYAC molecules and screening for 
inhibitors of 11β-HSD1. The fluorescent output connected with the activity of the enzyme can allow 
for selection of single cells producing inhibitors. The positive hits are then isolated through 
fluorescence activated cells sorting and further investigated to identify the active compounds. 
The yeast-based screening systems described here represent also a valid alternative to currently 
available assays for the screening of 11β-HSD1 inhibitors. Through the addition of the compounds to 
be tested in the growth medium, both RVY97 and RVY102 strains are efficient and adaptable systems 
for the screening and selection of cell permeable compounds with inhibitory activity, before 
progressing to expensive, low-throughput and time-consuming in vivo animal studies.  
 
The construction of the yeast strain RVY97 and RVY102 and their validation are object of a scientific 
publication currently under submission. Both strains and their assay mechanisms are protected by a 
patent. 
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The yeast-based platform investigated in this thesis intends to use the developed yeast strains for a 
single cell screening process in order to isolate events that produce 11β-HSD1 inhibitors. After eYACs 
preparation the yeast transformants will be cultivated in liquid media and the single cells screened by 
FACS upon treatment with cortisone. The positive hits (no fluorescent RVY97- and green fluorescent 
RVY102- cells) that indicate inhibition of the human enzyme are then sorted and further investigated 
in order to isolate and identify the active compounds. 
RVY97 and RVY102 respond properly to the treatment with cortisone, in fact the overall fluorescence 
output detected from the population indicates activity of the 11β-HSD1 enzyme on the hormone. 
Reversely, in presence of cortisone and carbenoxolone, a known 11β-HSD1 inhibitor, the output 
detected from the populations indicates inhibition of 11β-HSD1.  
Even though all the analyses conducted in this work were performed through FACS, the assays 
functionality was tested looking at the overall response of the isogenic population and not at the 
signal of single cells. Nevertheless, FACS analysis clearly led to the evidence that both isogenic 
populations, RVY97 and RVY102, do not respond uniformly to the treatment with the hormone.  
The background signal that results upon cortisone treatment does not influence the use of the two 
systems if the candidate inhibitors are added into the growth medium, since the response is detected 
from the entire population. However, the heterogeneous response would have important effects on 
the single cell screening mode that the final platform intends to use, thus, causing the presence of 
many false-positive events. For this reasons, further optimizations on the yeast strains developed are 
needed to ensure a more uniform response of the populations to cortisone and consequently to 
lower the presence of false positives.  
The heterogeneous response in a yeast isogenic population has been largely studied in the past and, 
among many possible causes, the non-uniform inheritance of the two 2μ plasmids used for the 
strains construction is most likely the origin of the not homogenous response. Both RVY97 and 
RVY102, respectively, contain two 2μ plasmids carrying 11β-HSD1 and GR expression cassettes. The 
amount and ratio of these two mammalian proteins need to be uniform and constant within the cells 
of an isogenic population in order to efficiently cooperate and trigger the downstream cascade in 
every single cell.  
The use of the ectopic 2μ plasmids rather than the genomically integrated constructs was chosen in 
order to maximize the expression of the two mammalian proteins, essential for the response of the 
yeast strains to the treatments with the hormone. In fact, this was the only strategy that allowed a 
proper response of the strains to the treatments with cortisone. 
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During the work, it has been demonstrated that the sensitivity of the developed assays to cortisone 
improves significantly when Pdr5p is inhibited, due to the higher intracellular levels of cortisone.  
Due to this evidence, Pdr5 gene deletion might allow for a significant response of the developed 
strains to cortisone even in presence of lower levels of 11β-HSD1 and GR expressed. For this reason, 
the single or multi-copy integration of the 11β-HSD1 and GR expression constructs in the genome, 
that would lead to lower levels of the mammalian proteins in the yeast cells but to higher genetic 
uniformity, may be, together with the Pdr5 gene deletion, the best strategy to achieve both, a good 
sensitivity of the systems and a reduction of the background signal upon cortisone treatments in the 
final assay strains. 
 
In order to increase the amount of triterpenoids synthetized in the yeast assay strains and thus to 
enhance the possible effects of these molecules towards the enzyme 11β-HSD1, the developed 
strains could be functionally re-engineered. Downregulation of the erg7 gene, responsible for the 
expression of the yeast lanosterol synthase, would lead to accumulation of 2,3 epoxy-squalene 
within the yeast cells. This metabolite, the common precursor to all the triterpenoids, can strongly 
promote the cyclization process driven by the plant and chimeric triterpenoid synthases expressed in 
yeast thus increasing the production of triterpenoids within the single cells. 
 
Before progressing to the final eYACs preparation and screening, an important experiment to 
perform can be the reproduction of a biosynthetic pathway for a known 11β-HSD1 inhibitor in the 
yeast assay strains. This will provide important information about the overall mechanisms of the 
screening strategy here investigated and can be used as positive control strain for the final screening 
procedure. Some efforts were spent in this work for the reconstitution of the biosynthetic pathway 
of glycerretinic acid in the RVY97 and RVY102 strains. Despite the presence of all the genetic 
information to reproduce the pathway, in a first analysis, the synthesis of the glycerretinic acid was 
not detected. 
 
Finally, although still some work needs to be done, the results of this PhD thesis strongly support the 
initial innovative and challenging idea for production and screening of novel 11β-HSD1 inhibitors.  
I believe that this work can introduce in the scientific community some innovative concepts and 
information, and can be a source of inspiration for advances in drug-discovery processes. 
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All the PCRs, restriction reactions and ligations performed in this work followed standards protocols 
whether not otherwise specified.  
 
Triterpenoid synthase cDNAs cloning  
The triterpenoid synthase cDNAs (Table 4.1) have been codon optimized for expression in yeast S. 
cerevisiae and provided by Evolva. All cDNAs were cloned without stop codon and in frame with a 
sequence coding for a polyhistidine tag in the vector pET300 CT-His, prior to be used for the 
application of the DNA family and semi-synthetic shuffling methods. Bacterial cells containing the 
plasmids carrying the cDNAs were inoculated in 3 ml of Luria Broth medium with 100 μg/ml 
Ampicillin and incubated overnight at 37°C shaking at 180 rpm. Small scale preparation of DNA 
plasmid was performed with the PureYield Plasmid Miniprep System kit following manufacturer’s 
instructions. The final DNA concentration was measured with NanoDrop 2000c spectrophotometer. 
Based on the similarity values of the triterpenoid synthase cDNAs, three groups of sequences were 
selected for the application of the shuffling methods (Fig. 4.1). Each group consisted of 4 different 
cDNAs sharing between 73% and 85% of the nucleotide sequences. 
 
 
DNA family shuffling 
The original DNA family shuffling protocol (Crameri et al., 1998) was adapted in order to obtain the 
best experimental outcome. Each cDNA molecule was initially PCR amplified from the recipient 
vector pET300 CT-His in order to collect large amount of material. The PCR was carried out with 
universal external primers T7 promoter and T7 reverse (Table 7.1) at a concentration of 0.5 μM each, 
together with 1 unit Phusion HF DNA Polymerase, 1x Phusion HF Buffer, 200 μM of each dNTP and 1-
5 ng of template in a total volume of 20 μl. The PCR program employed consisted of 95°C for 5 min as 
initial step, followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 
seconds, elongation at 72°C for 3 min. A final elongation step of 5 min at 72°C was performed. PCR 
products were analysed on a 1% (w/v) agarose gel with 1 μg/ml ethidium bromide and visualized 
with an UV-transilluminator. All DNA products were individually purified from agarose gel through 
NucleoSpin Extract II kit according to manufacturer’s instructions and the concentration was 
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measured using NanoDrop 2000c. According to the original protocol, an equimolar mixture (1-4μg) of 
molecules to treat together was set before to proceed with the DNaseI reaction.  
The DNA equimolar mixture was digested with 0.0075 U of DNaseI at 25°C for 4-10 min. The reaction 
mixture was completed with 1x DNaseI buffer in a total volume of 40 μl. After incubation the 
reaction was stopped with high excess of EDTA (final concentration: 20 mM) and loaded in a 2% 
(w/v) agarose gel for DNA electrophoresis (20 min at 130 Volts). DNA fragments between 30 and 150 
bp were purified from agarose gel with NucleoSpin Extract II kit according to manufacturer’s 
instructions and employed for the subsequent reassembling PCR. 
DNA fragments (15ng/μl) were prepared in a reaction mixture together with 1U Phusion HF DNA 
polymerase, 1x Phusion HF Buffer and 200 μM of each dNTP. The recombination PCR was carried out 
using the following conditions: first denaturation step at 95°C for 1 minute and then 50 cycles of 95°C 
for 30 seconds, 52°C for 1 minute, 72°C for 2 minute followed by a final amplification step at 72°C for 
10 min. Part of the PCR product was loaded on a 1% (w/v) agarose gel, stained with ethidium 
bromide 1 μg/ml and visualized under UV light. 
Full length chimeric sequences were amplified using as template the primerless PCRs product at 
different dilutions. Amplifications were carried out under the following conditions: one step of 95°C 
for 5 min followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 
seconds, elongation at 72°C for 2.30 min. A final elongation step at 72°C for 5 min was performed. 
Each reaction consisted of 1 unit FIREPol DNA Polymerases, 1x reaction Buffer B, 2.5 mM MgCl2, 200 
μM each dNTP, 0.5 μM of each primer and as template a dilution of the primerless PCR product, in a 
total volume of 20 μl. Typically, several reactions with different template dilutions were performed 
to ensure the best amplification results. The products were verified on a 1% (w/v) agarose gel with 1 
μg/ml ethidium bromide. The right size DNA bands (2.3 kb) were purified using NucleoSpin Extract II 
kit. 
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DNA semi-synthetic shuffling  
Primer designing 
According to the sequences alignment in every group of cDNAs 10 conserved regions were identified 
and selected for common primers designing. Right and left overlapping primers of 10-15 bp were 
drawn to bind all four genes of the same group in the same regions. 10 couple of primers were 
designed for each group of genes (Table 7.1). 
 
Table 7.1. List of oligonucleotides employed in the DNA semi-synthetic Shuffling method. 
Primer Name Sequence (5'→ 3') Application 
EV47484950 For1 CAAACATGGGAGTTC Shuffling group I 
EV47484950 Rev1 GAACTCCCATGTTTG Shuffling group I 
EV47484950 For 2 GATGGACACTGGCCTGC Shuffling group I 
EV47484950 Rev 2 GCAGGCCAGTGTCCATC Shuffling group I 
EV47484950 For3 ATGAGGATCTTGGGAG Shuffling group I 
EV47484950 Rev3 CTCCCAAGATCCTCAT Shuffling group I 
EV47484950 For4 CCAGCAAAGATGTGGTG Shuffling group I 
EV47484950 Rev4 CACCACATCTTTGCTGG Shuffling group I 
EV47484950 For5 AGATGGCCATTCAACAA Shuffling group I 
EV47484950 Rev5 TTGTTGAATGGCCATCT Shuffling group I 
EV47484950 For6 ATGCAATCTTTCGGT Shuffling group I 
EV47484950 Rev6 ACCGAAAGATTGCAT Shuffling group I 
EV47484950 For7 GATCATGGATGGCAAGT Shuffling group I 
EV47484950 Rev7 ACTTGCCATCCATGATC Shuffling group I 
EV47484950 For8 GAATGGTTGGAGCTTCTTAA Shuffling group I 
EV47484950 Rev8 TTAAGAAGCTCCAACCATTC Shuffling group I 
EV47484950 For9 TGGTACGGCAATTGGGG Shuffling group I 
EV47484950 Rev9 CCCCAATTGCCGTACCA Shuffling group I 
EV47484950 For10 CCATTACACAGGGCTGC Shuffling group I 
EV47484950 Rev10 TGCTGCCCTGTGTAAAGG Shuffling group I 
EV525354C405 For1 TGGGAGTTCGACCCT Shuffling group II 
EV525354C405 Rev1 AGGGTCGAACTCCCA Shuffling group II 
EV525354C405 For2 GATGGACATTGGCCTGG Shuffling group II 
EV525354C405 Rev2 CCAGGCCAATGTCCATC Shuffling group II 
  EV525354C405 For3 CTAATGATGGGGAAGG Shuffling group II 
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EV525354C405 Rev3 CCTTCCCCATCATTAG Shuffling group II 
EV525354C405 For4 CCAGGTAGGATGTGGTG Shuffling group II 
EV525354C405 Rev4 CACCACATCCTACCTGG Shuffling group II 
EV525354C405 For5 CATGATATTGATTGGAA Shuffling group II 
EV525354C405 Rev5 TTCCAATCAATATCATG Shuffling group II 
EV525354C405 For6 ATGTTGTGTTGTTGGGT Shuffling group II 
EV525354C405 Rev6 ACCCAACAACACAACAT Shuffling group II 
EV525354C405 For7 CACGGCTGGCCAAT Shuffling group II 
EV525354C405 Rev7 ATTGGCCAGCCGTG Shuffling group II 
EV525354C405 For8 CCTGCTGAGACTTTTGG Shuffling group II 
EV525354C405 Rev8 CCAAAAGTCTCAGCAGG Shuffling group II 
EV525354C405 For9 TGGGGAGTCTGCTT Shuffling group II 
EV525354C405 Rev9 AAGCAGACTCCCCA Shuffling group II 
EV525354C405 For10 AACACAGGCTGGGCTATG Shuffling group II 
EV525354C405 Rev10 CATAGCCCAGCCTGTGTT Shuffling group II 
EV42434849 For1 TCTACTAACAACTT Shuffling group III 
EV42434849 Rev1 AAGTTGTTAGTAGA Shuffling group III 
EV42434849 For2 CTACAGGCAAGTGATGG Shuffling group III 
EV42434849 Rev2 CCATCACTTGCCTGTAG Shuffling group III 
EV42434849 For3 ACATATATTGTCATCAAAA Shuffling group III 
EV42434849 Rev3 TTTTGATGACAATATATGT Shuffling group III 
EV42434849 For4 TGGGGTAAAACCTGG Shuffling group III 
EV42434849 Rev4 CCAGGTTTTACCCCA Shuffling group III 
EV42434849 For5 ATGAGTTATCTTTA Shuffling group III 
EV42434849 Rev5 TAAAGATAACTCAT Shuffling group III 
EV42434849 For6 CCTTTACTTACTAGAT Shuffling group III 
EV42434849 Rev6 ATCTAGTAAGTAAAGG Shuffling group III 
EV42434849 For7 GACTTTAGAAGTATGT Shuffling group III 
EV42434849 Rev7 ACATACTTCTAAAGTC Shuffling group III 
EV42434849 For8 AAGTGCTGTTTACTTTT Shuffling group III 
EV42434849 Rev8 AAAAGTAAACAGCACTT Shuffling group III 
EV42434849 For9 TGGTATGGCAATTGGGG Shuffling group III 
EV42434849 Rev9 CCCCAATTGCCATACCA Shuffling group III 
EV42434849 For10 CAAGCCGAAAGAGATC Shuffling group III 
EV42434849 Rev10 GATCTCTTTCGGCTTG Shuffling group III 
T7 promoter TAATACGACTCACTATAGGG Upstream Universal 
T7 reverse TAGTTATTGCTCAGCGGTGG Downstream Universal 
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Fragments amplification 
Eleven fragments from each sequence were amplified by PCR. The typical length of these fragments 
ranged between 100-500 bp. The amplification mix consisted of 1 Unit of FIREPol DNA Polymerase, 
1x reaction Buffer B, 2.5 mM MgCl2, 200 μM of each dNTP and 0.5 μM of each primer in a total 
volume of 20 μl. As template 1-5 ng of the corresponding cDNA sequence was added to the reaction 
mixture. PCR conditions were as follows: one step of 95°C for 5 min, 35 cycles of 95°C for 30 seconds, 
52°C for 30 seconds and elongation at 72°C for 20 seconds. Finally an elongation step of 5 min at 
72°C was performed. In the case of low quality results the PCR was repeated decreasing the 
annealing temperature to 38°C. PCR products were analysed on a 1.5% (w/v) agarose gel with 1 
μg/ml ethidium bromide and visualized with an UV-transilluminator. All DNA fragments were 
individually purified from agarose gel using NucleoSpin Extract II kit according to manufacturer’s 
instructions and the DNA concentration measured with NanoDrop 2000c.  
 
Primerless PCRs 
The amplified fragments were used as unique DNA material in an overlap extension PCR. Each group 
of fragments amplified with the same primers and belonging to the four different cDNAs of the same 
group were organized in equimolar mixtures of 70 ng and added to the reaction. The final amount of 
DNA fragments in the reaction was 770 ng in a total volume of 50 μl. The reaction mixture was 
completed with 1 unit Phusion HF DNA Polymerase, 1x Phusion HF Buffer and 200 μM of each dNTP. 
Recombination PCR was carried out using the following conditions: first denaturation step at 95°C for 
1 minute and then 50 cycles of 95°C for 30 seconds, 52°C for 1 minute, 72°C for 1 minute followed by 
a final amplification step at 72°C for 5 min. Afterwards 10 μl of the PCR product were loaded on a 1% 
(w/v) agarose gel stained with 1 μg/ml ethidium bromide and visualized under UV light. 25 μl from 
the first recombination PCR were used as template in a second primerless PCR. 1 unit of Phusion HF 
DNA Polymerase, 1x Phusion Buffer and 200 μM each dNTP were added to 25 μl of the previous 
reaction in a final volume of 50 μl. PCR conditions for the second recombination PCR consisted of 
95°C for 5 min as initial step, followed by 25 cycles of denaturation at 95°C for 30 seconds, annealing 
at 55°C for 30 seconds, elongation at 72°C for 1 minute. A final elongation step of 5 min at 72°C was 
added. 10 μl of the PCR product were verified on a 1% (w/v) agarose gel with 1 μg/ml ethidium 
bromide and visualized with an UV-transilluminator. 
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Full-length chimeric cDNAs amplification  
As final step of the DNA semi-synthetic shuffling protocol, the full length chimeric sequences were 
amplified from the Primerless PCR products. For each group of parental cDNAs, left and right primers 
binding upstream and downstream of all the four different sequences were designed (Table 7.2). 
HindIII  and SacII restriction sites were added to the forward and reverse primers, respectively, in 
order to perform further cloning steps. Amplifications were carried out at the following conditions: 
one step of 95°C for 5 min followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 
55°C for 30 seconds, elongation at 72°C for 2.30 min. A final elongation at 72°C for 5 min was 
performed. Each reaction consisted of 1 U FIREPol DNA Polymerases, 1x reaction Buffer B, 2.5 mM 
MgCl2, 200 μM each dNTP, 0.5 μM of each primer and as template serial dilutions of the second 
primerless PCR product, in a total volume of 20 μl. Typically, several reactions with different template 
dilutions were performed to ensure the best results. The products were verified on a 1% (w/v) 
agarose gel with 1 μg/ml ethidium bromide. The right size DNA bands (2.3 kb) were excised and 
purified using NucleoSpin Extract II kit. 
 
Table 7.2. Primers used in the final chimerc cDNA amplification of the semi-synthetic DNA Shuffling method. 
Primer Name Sequence (5'→ 3') Application 
UniversalRevSacII GCATACCCGCGGTCAGTGGTGGTGGTGGTGGTG Final PCR  
ForEv47HindIII GCATACAAGCTTAAAATGTGGAAATTGAAAATTGG Final PCR  
ForEv48HindIII GCATACAAGCTTAAAATGTGGAGATTGAAAATTGC Final PCR  
ForEv49HindIII GCATACAAGCTTAAAATGTGGAAATTGAAAATTGC Final PCR  
ForEv50HindIII GCATACAAGCTTAAAATGTGGAGATTGATGACTGC Final PCR  
For525354HindIII GCATACAAGCTTAAAATGTGGAAATTGAAAATTGC Final PCR  
ForC405HindIII GCATACAAGCTTAAAATGTGGAAGCTCAAGGTTGC Final PCR  
ForEV42HindIII GCATACAAGCTTAAAATGTGGAAATTGAAAATTGC Final PCR  
ForEV43HindIII GCATACAAGCTTAAAATGTGGAGAATTAAAATTGC Final PCR  
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cDNA library construction  
The mixture of chimeric cDNAs obtained from the application of the DNA semi-synthetic shuffling 
was cloned into entry vectors for the eYACs construction. The same procedure in parallel was 
performed for the ten parental cDNA molecules (Table 4.1) used as starting material in the DNA 
shuffling protocols.  
Double digestion of chimeric sequences and entry vectors 
The mixture of sequences obtained from the mutagenesis protocol and each destination entry vector 
were double digested, in separate reactions, with HindIII and SacII enzymes. The reaction typically 
consisted of 1-2 μg of DNA, 1x Cutsmart Buffer and 10 U of each restriction enzyme in a total volume 
of 50 μl. Plasmids digestion was usually performed for 2 hours at 37°C. The reaction was verified 
through DNA electrophoresis and the right size band was purified from agarose gel using NucleoSpin 
Extract II kit. The mixture of chimeric DNA was digested at 37°C overnight and the products purified 
directly from the reaction mixture with NucleoSpin Extract II kit. 
 
 
Cloning of chimeric products into the entry vectors  
The mixture of genes obtained from the DNA semi-synthetic shuffling, after digestion, was cloned 
separately into six destination entry vectors (Table 7.3). All ligation reactions consisted of 400 U of T4 
DNA ligase (NEB), 1x T4 DNA ligase Buffer in a final volume of 10 μl or 20 μl. 20 ng of digested vector 
were used as destination recipient plasmid and according to the ratio 1:5 (vector: insert) a certain 
amount of digested DNA insert was added to each reaction. All the ligation reactions were performed 
at 4°C for 8 hours followed by a step of 6 hours at 16 °C. After ligation the DNA was purified from the 
reaction with NucleoSpin Extract II kit and used to transform chemically competent high efficiency 
E.coli NEB 5-alpha cells according to manufacturer’s instructions. Transformed cells were plated on 
LB agar plates supplemented with Ampicillin 100 μg/ml for selection of positive clones. Several 
ligation processes and transformation steps were performed during the work in order to obtain a 
high number of colonies and representation of high numbers of chimeric cDNAs in the final library. 
After every transformation process the colonies were collected from the agar plates and conserved 
in a final solution of 50% glycerol at -80°C. Exactly the same procedure was used to construct the 
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library of parental cDNAs in the recipient entry vectors. Colony PCR procedures and restriction 
reactions of random purified plasmids were used to assess the quality of the final cDNA libraries.  
 
Table 7.3. List of entry vectors used as recipient plasmids for the chimer triterpenoid synthases and parental 
cDNAs. In table are indicated yeast promoter and terminator contained in each vector. A schematic map of 
these vectors can be visualized in figure 4.7. 
Vector Yeast Promoter 
Yeast 
Terminator 
Application 
pEVE3591  pTDH3 CYC1t cDNA library and eYACs construction 
pEVE3611  pADH1 PGK1t cDNA library and eYACs construction 
pEVE3612  pPGK1 ADH2t cDNA library and eYACs construction 
pEVE3613  pPYK1 TEF1t cDNA library and eYACs construction 
pEVE3614  pTEF1 ENO2t cDNA library and eYACs construction 
pEVE3618  pTPI1 TDH1t cDNA library and eYACs construction 
 
 
To confirm the success of the DNA semi-synthetic shuffling method applied, more than 60 new DNA 
molecules obtained through shuffling and represented in the cDNA library, were sent for sequencing 
to Microsynth AG. Results were analysed and compared with the parental cDNAs in a multiple 
sequences alignment using ClustalX software.   
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eYACs construction 
DNA preparation 
As previously described, all cDNA molecules used in the eYACs preparation were cloned into a group 
of entry vectors between a yeast promoter and a yeast transcription terminator signal. 3 ml of the 
chimeric genes library previously assembled and 600 μl of the parental cDNAs library were separately 
inoculated from -80 °C glycerol stocks into two solutions of 250 ml LB medium with 100 μg/ml 
Ampicillin and incubated overnight at 37°C shaking at 180 rpm. Isolation of DNA plasmids was 
performed using the PureYield Plasmid MaxiPrep System following the manufacturer’s protocols. The 
purified DNA obtained from different MaxiPrep procedures was ethanol precipitated and 
concentrated in a low final volume. The final concentration was verified using NanoDrop 2000C 
spectrophotometer. 
 
  
Restriction digestion of the cDNA library  
Entry vectors containing triterpenoid synthase parental and chimeric cDNAs of interest, ARSH4, and 
URA3 auxotrophic marker were double digested with NotI and AscI. The S. cerevisiae replication 
signal ARSH4 and the URA3 auxotrophic marker genes cloned in different entry vectors were 
provided by Evolva and after treatment with AscI and NotI released the elements for replication and 
selection of the chromosomes in yeast. To limit the chances of spontaneous homologous 
recombination during eYAC construction a “non-funtional” exogenous cDNA library, provided by 
Evolva and previously cloned in the same mix of entry vectors was digested and added to the 
preparation. A total amount of 50 μg DNA per preparation was used for different eYAC construction 
experiments (Table 7.4). All digestion reactions were carried out in a total volume 40 μl with 50 U of 
NotI, 50 U of AscI and  1x Cutsmart Buffer. Reactions were incubated overnight at 37°C. The enzymes 
were then heat inactivated through incubation of the mixture at 65 °C for 20 min. In order to 
sequester away the short stopper fragment generated by NotI and AscI digestion, 500 μM of 
competing oligonucleotide were added to every reaction and the temperature was set at 70°C for 20 
min before to be cooled down at 25-20°C. 
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Table 7.4. DNA mixtures used in different eYACs preparation reactions.  
 
Reaction  
1 
Reaction  
2 
Reaction  
3 
Reaction  
4 
Reaction  
5 
Reaction  
6 
Reaction  
7 
ARSH4 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 
URA3 
expression 
cassette 
4.0% 4.0% 4.0% 4.0% 4.0% 4.0% 4.0% 
Parental 
trit. synthase 
cDNAs  
— 45.0% — — — 15.0% 15.0% 
Exogenous 
cDNA 
94.0% 49.0% 69% 44.0% 19.0% 69.0% 44.0% 
Chimeric  
trit. synthase 
cDNAs 
— — 25.0% 50.0% 75.0% 10.0% 35.0% 
 
 
Concatenation reaction and eYAC arms ligation 
In order to concatenate the expression cassettes, ATP at a final concentration of 5 mM, and 5.2 U of 
T4 ligase (Agilent) were added to each tube. Reactions were incubated 2 hours at room temperature. 
The ligase was then heat inactivated at 65 °C for 15 min. To check the degree of concatenation, the 
reactions were carefully pipetted using a 20 μl tips and the high molecular weight was detected by an 
increase in the viscosity of the DNA solution. eYAC arms containing LEU2  auxotrophic marker gene 
have been prepared and digested in advance at Evolva. 40 μg of YAC arms, 1x Cutsmart Buffer, 1mM 
ATP, 5.6 units of T4 ligase (Agilent) in a total of 60 μl were added to every eYAC preparation reaction 
and gently mixed by pipetting. Reactions were incubated 30 min at room temperature, and the ligase 
was heat inactivated at 65 °C for 15 min.  
 
 
Spheroplasts trasformation  
Two days before transformation, a single colony of EYS1019 yeast strain was inoculated into 50 ml of 
YPD broth at 30°C, shaking at 180 rpm for 24 hours. The day after 0.3 and 0.8 ml of the pre-culture 
were inoculated into 2 1000 ml YPD flasks and incubated overnight at 30 °C with shaking, till 3-5 
OD600. The next morning, OD600 of the cultures was measured and 1000-1100 OD600 units were 
harvested by centrifugation at 4000 rpm for 5 min. The supernatant was discarded and the cell pellet 
was washed twice, resuspending first in 50 ml of sterile nanopure water and then in 25 ml nanopure 
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water with 1M sorbitol. The solution was spun again at 4000 rpm for 5 min and the supernatant 
discarded before to resuspend the cells in 12.5 ml of SCE solution. The OD600 
 
was measured. 125 μl of 
100 T Zymolyase were added, and the cells were incubated horizontally at 30 °C for 30 min with 
gentle shaking at 50-70 rpm, measuring every 5-10 min the OD600, until it reached 20-30 % of the 
initial value. Once achieved the desired OD600 value, the tubes were centrifuged at 1000 rpm at room 
temperature for 5 min, the supernatant was discarded, 20 ml of 1M sorbitol were added to each 
tube and the cells were gently mixed. The centrifugation and resuspension steps were repeated two 
more times resuspending before in 20 ml of STC and then in 6 ml of STC containing 50 μg/ml of calf-
thymus DNA.  
One falcon tube (15 ml) with 300 μl of spheroplasts was prepared for each transformation 
experiment and for positive and negative controls. Each eYAC preparation was added to the 
spheroplasts and the mixture gently mixed. As positive control 4 ng of plasmid carrying the same 
auxotrophic markers of the eYACs were used. As negative control, sterile water substituted the DNA 
preparation. 3 ml of PEG solution were then added to each tube and the samples incubated 5 min at 
room temperature before pelleting at 1000 rpm for 5 min. The supernatant was discarded and the 
cells resuspended in 1 ml of SOS and incubated at 30 °C for 40 min without shaking. For plating,  top 
agar (2.5% noble agar and CSM-Leu), prewarmed at 45-50 °C, was used: 7 ml of molten top agar were 
mixed with the sample and the suspension was distributed onto SD (2% glucose) sorbitol 
transformation plates without leucine. The plates were incubated at 30 °C for 6 days, preventing 
drying. Transformants were restreaked as single colonies in SD (2% glucose) plates without uracil and 
leucine for further analysis. 
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Triterpenoids GC-MS detection 
Cloning and expression of the triterpenoid synthase cDNAs 
Four parental cDNAs codifying for β-amyrin synthases and 20 chimeric cDNAs were subcloned into 
pYES2.1 plasmid previously modified to accept HindIII and SacII digested fragments between GAL1 
promoter and CYC1 terminator. Transformation in EYS1019 yeast strain of all the plasmids was 
performed following a typical yeast lithium acetate transformation protocol (Gietz and Woods, 
2002). Positive transformants were selected on agar plates without uracil to confirm the presence of 
the plasmid. Before to progress to GC-MS analyses each colony was inoculated for 24 hours at 30°C 
and 195 rpm in SD (2% glucose) liquid medium without uracil. Then part of the colony was washed 
with sterile water and inoculated in 5 ml of SD (2% galactose) without uracil at final OD600 of 0.1 to 
trigger the cDNA expression under the control on GAL1 promoter. The cultures were then kept at 
30°C and shaken at 195 rpm for 24 hours. The day after, the samples were washed twice with sterile 
water and then centrifuged to collect the pellet. Positive EYS1019 colonies selected after eYAC 
transformation were grown on SD (2% Glucose) medium without leucine and uracil for 24 hour at 
30°C. The day after the cultures were diluted at 0.1 OD600 in the same medium and kept at 30°C for 
additional 72 hours. Finally the cultures were washed and collected prior to analyze the organic 
extracts through GC-MS. 
 
 
Organic phase extraction  
Each sample was resuspended in 1 ml of 60% ethanol solution and incubated at 78°C for 10 min with 
strong shacking. Afterwards samples were centrifuged at highest speed in a table top centrifuge and 
the supernatant was transferred to a 13 ml glass tube. Two volumes of hexane were added and the 
sample was vortexed thoroughly for 30 seconds. After a short spin the upper phase was transferred 
to glass vials and dried through EZ-2 Personal Evaporator according to manufacturer’s instructions. 
All the samples were then resuspended in 50 μl hexane and transferred in glass vials suitable for GC-
MS injection. 
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GC-MS analysis 
GC-MS analyses of the organic extracts were conducted using an Agilent 5973N mass spectrometer 
connected to a gas chromatograph 6890N (Agilent) with a DB-35ms (length: 30 m; diameter: 0.25 
mm; film thickness: 0.25 µm) capillary column. The injection temperature was 250°C and the column 
temperature program as follows: 1.5 min at 110°C followed by a rise to at a rate of 20°C/min 300°C. 
The final run time was 27 min. Helium with a flow rate of 1.2 ml/min was used as carrier gas. The 
interface temperature was 300°C and a splitless injection mode was used. 
 
Yeast-based 11β-HSD1 assays  
Strains construction and growth conditions  
All Saccharomyces cerevisiae strains constructed in this work (Table 7.5) derive from the S150-2B 
strain (MATa, his3-Δ1, leu2-3 112, trp1-289, ura3-52). Yeast precultures were grown in YP medium 
plus 2% glucose (YPD) at 30°C. The integration plasmids carrying the construct GRE-yEGFP and GRE-
TEV were provided by Evolva SA. The TEV and yEGFP genes are under the control of a 3xGRE+CYC1-
TATA promoter that efficiently activates downstream reporter constructs in yeast upon binding the 
glucocorticoid receptor (Picard et al., 1990). In RVY97 and RVY102 strains, the respective GRE-GFP 
and GRE-TEV constructs were integrated as a single copy into the ECM3 locus of chromosome XV of 
the yeast genome. Positive transformants were selected on YPD agar plates containing Hygromycin 
(200 μg/ml). In the RVY102 assay strain, the N-Degron fluorescent reporter protein construct (Evolva 
SA), controlled by GAL1 promoter was integrated as a single copy into the genome at the KIN1 locus 
of chromosome IV. The positive transformants were selected on YPD agar plates containing 
Nourseothricin (1 mg/ml). All integration processes were carried out using the lithium acetate 
transformation protocol (Gietz and Woods, 2002) and successful integration confirmed by PCR. Two 
plasmids carrying the murine Nr3c1 cDNA and the wild type HSD11B1 human cDNA codifying for GR 
and 11β-HSD1 respectively were provided by Evolva SA. Both sequences were amplified by PCR and 
cloned via TA cloning in pYES 2.1 (Invitrogen) downstream of the GAL1 promoter. The HSD11B1 cDNA 
was cloned without stop codon and in frame with a sequence coding for a polyhistidine tag. The 
GAL1- HSD11B1 expression cassette was then amplified by PCR from the pYES 2.1 vector and sub-
cloned into a plasmid with a TRP1 auxotrophic marker (pEVE2113) whereas Nr3c1 was kept in the 
pYES 2.1 (URA3). The transformation of both ectopic plasmids carrying the Nr3c1 and HSD11B1 
Rosario Vanella  Experimental Procedures 
85 
 
cDNAs was performed using the lithium acetate transformation protocol. Positive clones were 
selected on SD agar plates (2% glucose) lacking uracil and tryptophan for double plasmid selection. 
All the genetic constructs used for strain construction were confirmed by sequencing. 
All experiments with strains RVY96 or RVY97 and RVY101 or RVY102 were carried out in SD medium 
(2% glucose) without uracil and tryptophan for 24 hours and then washed and re-suspended in SD 
medium (2% galactose) without uracil and tryptophan for induction of GR and 11β-HSD1 expression. 
Cortisone and dexamethasone were added to the cultures from 28 mM stock solutions in DMSO to 
the required concentrations. 
 
Table 7.5. Genotypes of the yeast strains assembled in this work. 
Strain  Genotype 
RVY96 S1502B-ECM3::pCYC 3xGRE-yEGFP-tADH1  loxP-HygR-loxP  [Nr3c1-TRP1-2μ] 
RVY97 
S1502B-ECM3::pCYC 3xGRE-yEGFP-tADH1  loxP-HygR-loxP  [Nr3c1-TRP1-2μ] 
[HSD11B1-URA3-2μ] 
RVY101 
S1502B-ECM3::pCYC3xGRE-TEV-tADH1  loxP-HygR-loxP  KIN1::GAL1-Degron-tADH1  
loxP-NatR-loxP [Nr3c1-TRP1-2μ] 
RVY102 
S1502B-ECM3::pCYC3xGRE-TEV-tADH1  loxP-HygR-loxP  KIN1::GAL1-Degron-tADH1  
loxP-NatR-loxP [Nr3c1-TRP1-2μ] [HSD11B1-URA3-2μ] 
 
 
Validation of the assays with carbenoxolone 
Yeast strains were maintained for 24 hours in 2% glucose SD medium without uracil and tryptophan. 
After 24 hours, the cells were diluted to an OD600 of 0.1 in 2% galactose SD medium lacking uracil and 
tryptophan. The cultures were grown for an additional 18 hours in galactose to induce 11β-HSD1, GR 
and the N-Degron fluorescent fusion protein expression and then divided into 3 ml subcultures. 
Cortisone was added to the cultures from a 28 mM stock solution in DMSO to the required 
concentrations. At different time points the cells were collected, resuspended in 1x PBS and analysed 
using a FACSCalibur flow cytometer from Becton Dickson (San Jose, CA). Every experiment was 
repeated independently at least three times. 
The specificity of the signal upon treatment with cortisone was confirmed with strains in which the 
plasmids carrying the 11β-HSD1 expression cassette were replaced by the equivalent empty 
plasmids. Except for the missing 11β-HSD1 expression construct, the strains were identical to the two 
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parental assay strains RVY97 and RVY102. In the validation of the assays the 11β-HSD1 inhibitor 
carbenoxolone (CBX) (stock solution 1 mM/water) was added to 106 cells together with cortisone to 
reach a final concentration of 0.1, 0.3, 1.0 and 3.0 μM, respectively. Cells were incubated for 6 hours 
and after washing in 1x PBS the samples were analysed by FACS. Both RVY97 and RVY102 strains 
were tested with carbenoxolone under identical conditions. 
Figure 4.19a shows the green fluorescence of RVY102 samples treated with 1000 μM cortisone and 
increasing concentration of carbenoxolone (CBX). The percentage of yEGFP degradation events 
obtained upon treatment of RVY102 cells with 1000 μM cortisone and no carbenoxolone was set at 
1. This value was used as reference for the normalization of the other degradation values. In order to 
get the fluorescence values plotted, the formula (fluorescence = 1- degradation value) was used. 
 
 
Flow cytometric and fluorescence microscopy analysis of yeast fluorescence 
250 μl of yeast culture volume were centrifuged and re-suspended in 500 μl 1x PBS. FACS analyses 
were performed using the FACSCalibur instrument. The instrument settings were as follows:  log 
forward scatter (FSC) E00; log side scatter 2 (SSC) at 458 V, log FL1 fluorescence at 468 V and log FL2 
fluorescence at 460 V. The yEGFP fluorescence was excited at 488 nm and collected through 530/30 
nm band-pass filter on the FL1 channel. The tdTomato fluorescence was excited at 488 nm and 
collected through 585/42 nm band-pass filter on the FL2 channel. For multicolour analysis of the 
strain RVY102, fluorescence compensation (FL2- 20.8% FL1) was manually set using single colour cell 
controls. The typical sampling rate was 200 events/s, and the typical sample size was 10’000 cells per 
measurement. The data were analysed with FlowJo vX.0.7 software. For fluorescence images the 
samples were taken at different dilutions and examined for green and red fluorescence under the 
optical microscope BX41 (Olympus) equipped with FITC and TRITC filter sets using a 40x 
magnification lens and an exposure time of 1/3 sec. 
 
Rhodamine 6G accumulation and efflux  
The strains RVY97 and RVY102 (OD600 of 0.1) were incubated in the presence of FK506 (10 μM) or 
DMSO (control) for 20 min followed by incubation with 5 μM Rhodamine 6G for 1 hour at 30°C. 
10’000 cells of each population were analysed by FACS. 
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Sensitivity to cortisone in presence of FK506 
The 11β-HSD1 assay strains RVY97 and RVY102 were tested for the cortisone induced gene 
transactivation after incubation with 10 μM FK506 or DMSO for 20 min at 30°C.  
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Cells 
EYS1019 (yeast strain)           (Kindly provided by Evolva) 
NEB 5-alpha Competent E. coli                              (NEB, Cat. No C2988J) 
NEB 5-alpha Competent E. coli (High Efficiency)                (NEB, Cat. No C29871) 
RVY101 (yeast strain)            (Constructed in this work) 
RVY102 (yeast strain)             (Constructed in this work) 
RVY96 (yeast strain)             (Constructed in this work) 
RVY97  (yeast strain)             (Constructed in this work) 
S150-2B (yeast strain)           (Kindly provided by Prof. Dr. Georg Lipps) 
 
Table 8.1. Genotypes of the bacterial and yeast strains used in this study. 
Strain Genotype 
NEB 5-alpha Competent E.Coli 
(Subcloning Efficiency) 
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80Δ (lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
NEB 5-alpha Competent E. 
coli  (High Efficiency) 
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
EYS1019 MATalpha his3Δ0 leu2Δ0 lys2Δ0 trp1Δ0 ura3Δ0 arg4Δ0 
S150-2B 
MATa, his3-Δ1, leu2-3 112, trp1-289, ura3-52 
 
RVY96 
S1502B-ECM3::pCYC 3xGRE-yEGFP-tADH1  loxP-HygR-loxP  
[Nr3c1-TRP1-2μ] 
RVY97 
S1502B-ECM3::pCYC 3xGRE-yEGFP-tADH1  loxP-HygR-loxP  
[Nr3c1-TRP1-2μ] [HSD11B1-URA3-2μ] 
RVY101 
S1502B-ECM3::pCYC3xGRE-TEV-tADH1  loxP-HygR-loxP 
KIN1::GAL1 Degron-tADH1  loxP-NatR-loxP [Nr3c1-TRP1-2μ] 
RVY102 
S1502B-ECM3::pCYC3xGRE-TEV-tADH1  loxP-HygR-loxP 
KIN1::GAL1 Degron-tADH1 loxP-NatR-loxP [Nr3c1-TRP1-2μ] 
[HSD11B1-URA3-2μ] 
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Enzymes and DNA ladders 
1kb plus DNA Ladder                           (Invitrogen, Cat. No. 15615-016) 
AscI                    (NEB, Cat. No. R0558S) 
FIREPol DNA Polymerase                  (Solis BioDyne, Cat. No. 01-01-00500) 
HindIII-HF                                             (NEB, Cat. No. R3104M) 
NotI-HF                                 (NEB, Cat. No. R3189L) 
Phusion High-Fidelity DNA Polymerase               (NEB, Cat. No. M0530L) 
Quick-Load 1 kp DNA Ladder                                (NEB, Cat. No. N0468S) 
Quick-Load 50 bp DNA Ladder                               (NEB, Cat. No. N0473S) 
SacII                    (NEB, Cat. No. R0157L) 
T4 DNA Ligase                               (NEB, Cat. No. M0202S) 
T4 DNA Ligase                       (Agilent, Cat. No. 600011) 
Zymolyase 100T                    (Zymo Reasearch, Cat. No. E1005) 
 
 
Products and reagents 
10x Buffer B                    (Solis BioDyne, Cat. No. 01-01-00500) 
10X Cutsmart Buffer                                             (NEB, Cat. No. B7204S) 
10X T4 DNA Ligase Buffer (with ATP)                                                                           (NEB, Cat. No. B0202S) 
5x Phusion HF reaction Buffer                                                                               (NEB, Cat. No. B0518S) 
Adenine                  (Sigma-Aldrich, Cat. No. A8626) 
Agar                                (Sigma-Aldrich, Cat. No. A1296) 
Ampicillin                            (Carl Roth, Cat. No K029.1) 
ATP                         (Fermentas Cat. No. R0441) 
CaCl2                                (Sigma-Aldrich, Cat. No. 223506) 
Calf thymus DNA               (Sigma-Aldrich, Cat. No. D4522) 
Carbenoxolone                  (Sigma-Aldrich, Cat. No. C4790) 
Cortisone                  (Sigma-Aldrich, Cat. No. C2755) 
CSM-Leu                     (MPBio, Cat. No. 114510512) 
CSM-Leu-Ura                    (MPBio, Cat. No. 114520212) 
D(+)-Galactose                   (Roth, Cat. No. 4987.2) 
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Dexamethasone                (Sigma-Aldrich, Cat. No. D4902) 
Dimethyl Sulfoxide          (Thermo Scientific, Cat. No. 20688) 
dNTPs Mix                                                 (Solis BioDyne, Cat. No. 02-31-00020) 
EDTA              (Sigma-Aldrich, Cat. No. 1233508) 
Ethanol                               (Sigma-Aldrich, Cat. No. 02854) 
Ethidium Bromide                                            (Sigma-Aldrich, Cat. No. E1510) 
FK-506 monohydrate                              (Sigma-Aldrich, Cat. No. F4679) 
Gel Loading Dye Purple (6X)                 (NEB, Cat. No. B7024S) 
Glycerol                             (Sigma-Aldrich, Cat. No. G5516) 
Hexane                               (Sigma-Aldrich, Cat. No. 34859) 
Hydrocortisone                (Sigma-Aldrich, Cat. No. H0888) 
Hygromycin B (Hygr)                                          (Sigma-Aldrich, Cat. No. H3274) 
LB Broth with agar                                                                                             (Sigma-Aldrich, Cat. No. L2897) 
L-Histidine                                             (Sigma-Aldrich, Cat. No. 53320) 
Lithium acetate dihydrate                                                                                (Sigma-Aldrich, Cat. No. L4158) 
L-Leucine                                             (Sigma-Aldrich, Cat. No. 61819) 
L-Lysine                                (Sigma-Aldrich, Cat. No. L5501) 
L-Methionine                           (Sigma-Aldrich, Cat. No. M9625) 
L-Tryptophan                               (Sigma-Aldrich, Cat. No. 93659) 
Luria Broth                  (Sigma-Aldrich, Cat. No. L3522) 
MgCl2                     (Solis BioDyne, Cat. No. 01-01-00500) 
Noble Agar                                            (Difco, Cat. No. 214220) 
Nourseothricin (Nat)                             (Sigma-Aldrich, Cat. No. 74667) 
Peptone from meat and soybean meal                                          (Sigma-Aldrich, Cat. No. 93733) 
Polyethylene glycol 4000                  (Sigma-Aldrich, Cat. No. 5904) 
Rhodamine 6G                  (Sigma-Aldrich, Cat. No. R4127) 
Salmon Sperm DNA                             (Invitrogen, Cat. No. 15632-011) 
Sodium Citrate                        (Sigma-Aldrich, Cat. No. W302600) 
Sorbitol                                (Sigma-Aldrich, Cat. No. S1876) 
Tris base                                                                   (Sigma-Aldrich, Cat. No. 252859) 
Ultra PureTM Agarose                                         (Invitrogen, Cat. No. 15510-027) 
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Uracil                                (Sigma-Aldrich, Cat. No. 94220) 
Yeast Extract                                     (Sigma-Aldrich, Cat. No. 92144) 
Yeast Nitrogen Base without Amino Acids                                         (Sigma-Aldrich, Cat. No. Y0626) 
Yeast Synthetic Drop-out Medium Supplements  
without histidine, leucine, tryptophan and uracil            (Sigma-Aldrich, Cat. No. Y2001) 
α-D-Glucose                             (Sigma-Aldrich, Cat. No. 158968) 
 
Plasmids  
entry vectors (Table 7.3)                               (Kindly provided by Evolva) 
pET303/CT-His                                   (Life Technologies, Cat. No.K630001) 
pEVE1801                             (Kindly provided by Evolva) 
pEVE1807 (GAL1 promoter)                       (Kindly provided by Evolva) 
pEVE1889                         (Kindly provided by Evolva) 
pEVE2113                         (Kindly provided by Evolva) 
pYES2.1/V5-His-TOPO                                                                                      (Life Technologies, Cat. No. K4150-01) 
 
Kits 
PCR clean-up & Gel extraction: NucleoSpin Extract II     (Macherey-Nagel, Cat. No. 740 609) 
PureYield Plasmid Miniprep System                                                  (Promega, Cat. No. A1223) 
PureYield Plasmid Maxiprep System                       (Promega, Cat. No. A2393) 
pYES2.1 TOPO TA Expression Kit                 (Life Technologies, Cat. No. K4150-01) 
 
Instruments 
BX41, System Microscope                          (Olympus) 
Centrifuge 5418 R                         Eppendorf,5418.0000.017) 
Centrifuge 5804 R                           (Eppendorf,5805000.327) 
EZ-2 Personal Evaporator                                  (Genevac) 
FACS Calibur             (Becton Dickinson) 
Gas Chromatograph 6890N                   (Agilent) 
Mass Spectrometer 5973N                   (Agilent) 
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Multimage TM Light Cabinet               (Alpha Innotech) 
Nanodrop 2000c            (Thermo Scientific) 
peqSTAR 2X Gradient Thermocycler          (peqlab, 95-08002) 
T3000 Thermocycler                                       (Biometra) 
Thermomixer Comfort                          (Eppendorf, 5355000.011) 
U-RFL-T, Power Supply Unit                           (Olympus) 
 
Software and algorithms 
Basic Local Alignment Search Tool (BLAST)             (www.ncbi.nlm.nih.gov) 
BD CellQuest Pro Software                        (Becton Dickinson) 
Sequence Scanner v1.0                      (Applied Biosystems) 
FluroChem™ SP Alpha Innotech                  (Version 4.1.0) 
Compass data analysis 4.0                    (Bruker) 
FlowJo vX.0.7.                      (http://docs.flowjo.com/d2/) 
NanoDrop 2000/2000C                      (Version 1.4.1) 
Snap Gene ® Viewer                   (Version 1.5.3) 
ClustalX                                     (Version 2.1) 
 
Growth media preparation  
YPD: Yeast extract 10g/L , Peptone 20g/L, α-D-Glucose 20g/L 
SD w/o uracil (2% Glucose): Yeast nitrogen base without amino acids 6.7 g/L, Yeast synthetic drop-
out media supplement without uracil 1.92 g/L, α-D-Glucose 20 g/L 
SD w/o uracil (2% Galactose): Yeast nitrogen base without amino acids 6.7 g/L, Yeast synthetic drop-
out media supplement without uracil 1.92 g/L, D(+)-Galactose 20g/L 
SD w/o uracil and tryptophan (2% Glucose):  Yeast nitrogen base without amino acids 6.7 g/L, Yeast 
synthetic drop-out media supplement without uracil tryptophan histidine and leucine 1.39 g/L, 
leucine 380 mg/L, histidine 76 mg/L, α-D-Glucose 20 g/L 
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SD w/o uracil and tryptophan (2% Galactose):  Yeast nitrogen base without amino acids 6.7 g/L, Yeast 
synthetic drop-out media supplement without uracil tryptophan histidine and leucine 1.39 g/L, 
leucine 380 mg/L, histidine 76 mg/L, D(+)-Galactose 20g/L 
For agar plates production the equivalent media were completed with 20 g/L agar before 
sterilization. In plates preparation Glucose and Galactose were added at 2% (w/v) final concentration 
from a sterile solution of 20% (w/v) just after autoclaving. 
Eventual antibiotics were added to yeast agar plates after autoclaving at the final working 
concentration (Nat,60 μg/ml and Hygr, 200 μg/ml) 
 
Solutions 
SCE: (1M Sorbitol, 0.1M Sodium Citrate pH 7.6, 0.06M EDTA) 
STC: (0.98 M Sorbitol, 10 mM Tris pH 7.5, 10 mM CaCl2) 
PEG8000: (19.6% PEG 8000 w/v, 10 mM tris pH 7.5, 10 mM CaCl2) 
SOS: (2 M sorbitol, 7 mM CaCl2, 25 % v/v YPD medium) + Amino acid mix (URA, HIS, LEU, TRP, ADE, 
LYS, MET 20 mg/l each) + Water  
PBS (10x): (80.6mM sodium phosphate, 19.4mM potassium phosphate, 27mM KCl and 1.37M NaCl, 
pH 7.4) 
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